Form 8-K/A Brooklyn ImmunoTherapeut For: Mar 25
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 30, 2021 (March 25, 2021)
BROOKLYN IMMUNOTHERAPEUTICS, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware
|
001-11460
|
31-1103425
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
140 58th Street, Building A, Suite 2100
|
||
Brooklyn, New York
|
11220
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: (212) 582-1199
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading symbol
|
Name of each exchange on which registered
|
||
Common Stock
|
BTX
|
NYSE American
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934:
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
EXPLANATORY NOTE
As discussed more fully in our Current Report on Form 8-K filed with the Securities and Exchange Commission on March 31, 2021, which we refer to as the Original Filing, we completed our acquisition
of Brooklyn ImmunoTherapeutics LLC, or Brooklyn LLC, on March 25, 2021 pursuant to an agreement and plan of merger and reorganization dated August 12, 2020.
We are filing this Amendment No. 1 on Form 8-K/A to amend the Original Filing solely to include the historical financial statements and pro forma financial information described below. The audited
financial statements of Brooklyn LLC as of, and for the fiscal years ended, December 31, 2020 and 2019, which are required by Item 9.01(a) of Form 8-K, and the unaudited pro forma condensed combined financial statements of Brooklyn
ImmunoTherapeutics, Inc. for the fiscal year ended December 31, 2020, which are required by Item 9.01(b) of Form 8‑K, were not filed with the Original Filing, in accordance with rules of the Securities and Exchange Commission. We have elected to also
provide the audited financial statements of Brooklyn LLC as of December 31, 2018 and for the period from November 6, 2018 through December 31, 2018 and the audited financial statements of IRX Therapeutics, Inc. (predecessor to Brooklyn LLC) for the
period from January 1, 2018 through November 5, 2018. Except for the audited historical financial statements and the unaudited pro forma condensed combined financial statements referenced in Item 9.01 below, this Amendment No. 1 on Form 8‑K/A does
not amend or restate the Original Filing, nor does it modify or update the disclosures in the Original Filing affected by subsequent events or discoveries.
Item 9.01 |
Financial Statements and Exhibits.
|
(a) |
Financial Statements of Business Acquired
|
The following are financial statements are included as Exhibits 99.1 and 99.2, respectively, to this Amendment No. 1 on Form 8‑K/A and are incorporated by reference herein:
• |
audited financial statements of Brooklyn LLC as of, and for the fiscal years ended, December 31, 2020 and 2019; and
|
• |
audited financial statements of Brooklyn LLC as of December 31, 2019 and 2018 and for the fiscal year ended December 31, 2019, the period from November 6, 2018 through December 31,
2018, and the period from January 1, 2018 through November 5, 2018.
|
(b) |
Pro Forma Financial Information
|
The unaudited pro forma condensed combined financial statements of Brooklyn ImmunoTherapeutics, Inc. for the fiscal year ended December 31, 2020 are included as Exhibit 99.3 to
this Amendment No. 1 on Form 8-K/A and are incorporated by reference herein.
(d)
|
Exhibits
|
Exhibit
No.
|
Description
|
|
Consent of Marcum LLP
|
||
Audited financial statements of Brooklyn ImmunoTherapeutics LLC as of, and for the fiscal years ended, December 31, 2020
and 2019.
|
||
99.2 |
Audited financial statements of Brooklyn ImmunoTherapeutics LLC as of December 31, 2019 and 2018 and for the fiscal year ended December 31, 2019, the period from
November 6, 2018 through December 31, 2018, and the period from January 1, 2018 through November 5, 2018
|
|
Unaudited pro forma condensed combined financial statements of Brooklyn ImmunoTherapeutics, Inc. for the year ended December 31, 2020, including notes thereto
|
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
BROOKLYN IMMUNOTHERAPEUTICS, INC.
|
||
Dated: April 29, 2021
|
By:
|
/s/ Howard J. Federoff
|
Howard J. Federoff
|
||
Chief Executive Officer and President
|
2
Exhibit 23.1
Independent Registered Public Accounting Firm’s Consent
We consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-232141), (No. 333‑167352) and (No.
333-205052) and the Registration Statements on Form S-3 (No. 333-111538), (No. 333-105429), (No. 333-51650), (No. 333-80143), (No. 333-69383), (No. 333-40625), (No. 333-14129) and (No. 333-192496) of Brooklyn ImmunoTherapeutics, Inc. of our report
dated April 30, 2021 with respect to our audits of the financial statements of Brooklyn ImmunoTherapeutics, LLC (Successor) and IRX Therapeutics, Inc. (Predecessor) (the “Company”) as of December 31, 2020, 2019 and 2018 and for the fiscal years
ended December 31, 2020 and 2019 and for the period from November 6, 2018 through December 31, 2018 (Successor), and the period from January 1, 2018 through November 5, 2018 (Predecessor), which includes an explanatory paragraph as to the Company’s
ability to continue as a going concern, which report is included in this Amendment No. 1 on Form 8-K/A.
/s/ Marcum LLP
Marcum LLP
New York, New York
April 30, 2021
Exhibit 99.1
BROOKLYN IMMUNOTHERAPEUTICS, LLC
FINANCIAL STATEMENTS
Years ended December 31, 2020 and 2019
Table of Contents
|
Page
|
Report of Independent Registered Public Accounting Firm
|
1
|
|
|
Financial Statements
|
|
|
|
Balance Sheets
|
2 |
|
|
Statements of Operations
|
3 |
|
|
Statements of Changes in Members’ Equity
|
4
|
|
|
Statements of Cash Flows
|
5 |
|
|
Notes to Financial Statements
|
6
|
BROOKLYN IMMUNOTHERAPEUTICS, LLC
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Members and Board of Managers of
Brooklyn ImmunoTherapeutics, LLC
Opinion on the Financial Statements
We have audited the accompanying balance sheets of Brooklyn ImmunoTherapeutics, LLC (the “Company”) as of December 31, 2020 and 2019, the
related statements of operations, changes in members’ equity and cash flows for each of the two years in the period ended December 31, 2020, and the related notes (collectively
referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2020, in conformity with accounting principles generally accepted in the United States of America.
Change in Accounting Principle
As discussed in Notes 3 and 7 to the financial statements, the Company has changed its method of accounting for leases in 2020 due to the adoption of the guidance in ASC Topic 842, Leases (“Topic 842”).
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting
firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and
regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform
the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal
control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal
control over financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such
procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well
as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matters
The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1)
relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on
the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.
Fair Value of Contingent Consideration
Description of the Matter
As discussed in Note 5 to the financial statements, contingent consideration is recorded at fair value at the transaction date and subsequently revalued each reporting period, with changes in the fair value
recognized within the statement of operations. As of and for the year ended December 31, 2020, management recorded a total contingent consideration liability of $20.1 million and change in fair value of $19.2 million. Management utilized a
third-party valuation specialist to assist in estimating the contingent consideration fair value using the income approach, and the discounted cash flows were used to estimate the expected royalty payments to third parties.
Auditing management’s estimated fair value of contingent consideration is highly subjective and judgmental as the assumptions used in the fair value measurement, including the discount rate, the amount and timing
of cash flows, and the forecast of future product sales, are all based on significant inputs not observable in the market. This in turn led to a high degree of auditor judgment, subjectivity and effort in performing procedures related to the
fair value of contingent consideration and the audit effort involved the use of professionals with specialized skill and knowledge to assist in evaluating the audit evidence obtained.
How we Addressed the Matter in Our Audit
With the assistance of our valuation specialists, our audit procedures included, amongst others:
• |
We obtained an understanding of management’s process in regards to the methodology used and the factors considered around the inputs, sources of data used and assumptions and estimates made in determining the fair value of
contingent consideration, including those over management’s review of its third-party specialist valuation report.
|
• |
We tested the completeness and accuracy of the data used in the discounted cash flow model.
|
• |
We evaluated the appropriateness of the discounted cash flow model.
|
• |
We performed a sensitivity analysis on the discount rate used in the discounted cash flow model to determine the impact rate changes could have on the fair value.
|
/s/ Marcum llp
Marcum llp
We are uncertain as to the year we began serving consecutively as the auditor of the Company’s financial statements; however, we are aware that we have been the Company’s auditor consecutively since at least
2013.
New York, NY
April 30, 2021
1
BROOKLYN IMMUNOTHERAPEUTICS, LLC
BALANCE SHEETS
December 31,
|
||||||||
2020
|
2019
|
|||||||
Assets
|
||||||||
Current Assets:
|
||||||||
Cash
|
$
|
1,630,455
|
$
|
5,014,819
|
||||
Prepaid expenses and other current assets
|
102,322
|
86,668
|
||||||
Total Current Assets
|
1,732,777
|
5,101,487
|
||||||
|
||||||||
Long-Term Assets:
|
||||||||
Restricted cash
|
-
|
86,000
|
||||||
Property and equipment, net
|
594,106
|
653,763
|
||||||
Right of use assets - operating leases
|
2,092,878
|
-
|
||||||
Goodwill
|
2,043,747
|
2,043,747
|
||||||
In process research and development
|
6,860,000
|
6,860,000
|
||||||
Security deposits and other assets
|
453,252
|
363,621
|
||||||
Total Assets
|
$
|
13,776,760
|
$
|
15,108,618
|
||||
Liabilities and Members’ Equity
|
||||||||
Current Liabilities:
|
||||||||
Accounts payable
|
$
|
1,275,223
|
$
|
1,735,610
|
||||
Accrued expenses
|
1,051,020
|
1,520,841
|
||||||
Investor deposits
|
-
|
665,563
|
||||||
Loans payable
|
410,000
|
410,000
|
||||||
Current portion of lease liability
|
273,217
|
4,026
|
||||||
Current portion of PPP loan
|
115,972
|
-
|
||||||
Total Current Liabilities
|
3,125,432
|
4,336,040
|
||||||
Long-Term Liabilities:
|
||||||||
Contingent consideration
|
20,110,000
|
870,000
|
||||||
Lease liability, non-current
|
1,905,395
|
99,030
|
||||||
PPP loan, non-current
|
193,933
|
-
|
||||||
Other liabilities
|
22,863
|
60,445
|
||||||
Total Liabilities
|
25,357,623
|
5,365,515
|
||||||
Commitments and contingencies
|
||||||||
Members’ Equity:
|
||||||||
Class A membership units
|
23,202,005
|
18,177,692
|
||||||
Class B membership units
|
1,400,000
|
1,400,000
|
||||||
Class C membership units
|
1,000,000
|
1,000,000
|
||||||
Common units
|
197,873
|
106,937
|
||||||
Accumulated deficit
|
(37,380,741
|
)
|
(10,941,526
|
)
|
||||
Total Members’ Equity
|
(11,580,863
|
)
|
9,743,103
|
|||||
Total Liabilities and Members’ Equity
|
$
|
13,776,760
|
$
|
15,108,618
|
The accompanying notes are an integral part of these financial statements.
2
BROOKLYN IMMUNOTHERAPEUTICS, LLC
STATEMENTS OF OPERATIONS
Year ended December 31,
|
||||||||
2020
|
2019
|
|||||||
Operating Expenses
|
||||||||
General and administrative
|
$
|
3,296,851
|
$
|
3,721,490
|
||||
Research and development
|
3,951,253
|
5,156,266
|
||||||
Change in fair value of contingent consideration
|
19,240,000
|
-
|
||||||
Total operating expenses
|
26,488,104
|
8,877,756
|
||||||
Loss from operations
|
(26,488,104
|
)
|
(8,877,756
|
)
|
||||
Other Expenses
|
||||||||
Interest expense, net
|
(42,957
|
)
|
(59,298
|
)
|
||||
Total other expenses
|
(42,957
|
)
|
(59,298
|
)
|
||||
Net loss
|
$
|
(26,531,061
|
)
|
$
|
(8,937,054
|
)
|
The accompanying notes are an integral part of these financial statements.
3
BROOKLYN IMMUNOTHERAPEUTICS, LLC
STATEMENTS OF CHANGES IN MEMBERS’ EQUITY
Membership Equity
|
Accumulated Deficit
|
Total
Members’
Equity
|
||||||||||||||||||||||
Class A
|
Class B
|
Class C
|
Common
|
|||||||||||||||||||||
Balance - January 1, 2019
|
$
|
9,958,930
|
$
|
1,400,000
|
$
|
1,000,000
|
$
|
15,248
|
$
|
(2,004,472
|
)
|
$
|
10,369,706
|
|||||||||||
Stock based compensation:
|
||||||||||||||||||||||||
Amortization of restricted common units
|
-
|
-
|
-
|
91,689
|
-
|
91,689
|
||||||||||||||||||
Sale of members’ equity
|
8,218,762
|
-
|
-
|
-
|
-
|
8,218,762
|
||||||||||||||||||
Net loss
|
-
|
-
|
-
|
-
|
(8,937,054
|
)
|
(8,937,054
|
)
|
||||||||||||||||
Balance - December 31, 2019
|
18,177,692
|
1,400,000
|
1,000,000
|
106,937
|
(10,941,526
|
)
|
9,743,103
|
|||||||||||||||||
Implementation of new accounting principle
|
-
|
-
|
-
|
-
|
91,846
|
91,846
|
||||||||||||||||||
Stock based compensation:
|
||||||||||||||||||||||||
Amortization of restricted common units
|
-
|
-
|
-
|
90,936
|
-
|
90,936
|
||||||||||||||||||
Sale of members’ equity
|
5,024,313
|
-
|
-
|
-
|
-
|
5,024,313
|
||||||||||||||||||
Net loss
|
-
|
-
|
-
|
-
|
(26,531,061
|
)
|
(26,531,061
|
)
|
||||||||||||||||
Balance - December 31, 2020
|
$
|
23,202,005
|
$
|
1,400,000
|
$
|
1,000,000
|
$
|
197,873
|
$
|
(37,380,741
|
)
|
$
|
(11,580,863
|
)
|
The accompanying notes are an integral part of these financial statements.
4
BROOKLYN IMMUNOTHERAPEUTICS, LLC
STATEMENTS OF CASH FLOWS
Year ended December 31,
|
||||||||
2020
|
2019
|
|||||||
Cash Flows from Operating Activities:
|
||||||||
Net loss
|
$
|
(26,531,061
|
)
|
$
|
(8,937,054
|
)
|
||
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||
Change in fair value of contingent consideration
|
19,240,000
|
-
|
||||||
Depreciation and amortization
|
98,332
|
20,407
|
||||||
Equity compensation
|
90,936
|
91,689
|
||||||
Loss on operating sublease
|
-
|
103,350
|
||||||
Change in operating assets and liabilities:
|
||||||||
Prepaid expenses and other current assets
|
(15,654
|
)
|
(66,670
|
)
|
||||
Security deposits and other assets
|
(89,631
|
)
|
76,155
|
|||||
Accounts payable and accrued expenses
|
(930,207
|
)
|
(1,087,874
|
)
|
||||
Operating lease liability
|
11,580
|
(294
|
)
|
|||||
Other liabilities
|
25,361
|
-
|
||||||
Total adjustments
|
18,430,717
|
(863,237
|
)
|
|||||
Net Cash Used in Operating Activities
|
(8,100,344
|
)
|
(9,800,291
|
)
|
||||
Cash Flows from Investing Activities:
|
||||||||
Purchase of property and equipment
|
(38,675
|
)
|
(606,071
|
)
|
||||
Net Cash Used in Investing Activities
|
(38,675
|
)
|
(606,071
|
)
|
||||
Cash Flows from Financing Activities
|
||||||||
Proceeds from PPP loan
|
309,905
|
-
|
||||||
Proceeds from investor deposits
|
-
|
437,500
|
||||||
Proceeds from the collection of subscriptions receivable
|
-
|
850,000
|
||||||
Proceeds from sale of members’ equity
|
4,358,750
|
7,808,250
|
||||||
Net Cash Provided by Financing Activities
|
4,668,655
|
9,095,750
|
||||||
Net (Decrease) Increase in Cash
|
(3,470,364
|
)
|
(1,310,612
|
)
|
||||
Cash and Restricted Cash - Beginning of Period
|
5,100,819
|
6,411,431
|
||||||
Cash and Restricted Cash - End of Period
|
$
|
1,630,455
|
$
|
5,100,819
|
||||
Cash and Restricted Cash consisted of the following:
|
||||||||
Cash
|
1,630,455
|
5,014,819
|
||||||
Restricted Cash
|
-
|
86,000
|
||||||
$
|
1,630,455
|
$
|
5,100,819
|
|||||
Supplemental Disclosures of Cash Flow Information:
|
||||||||
Cash paid during the period for:
|
||||||||
Interest
|
$
|
-
|
$
|
-
|
||||
Income taxes
|
$
|
-
|
$
|
-
|
||||
Non-cash investing and financing activities:
|
||||||||
Investor deposits for sale of members’ equity
|
$
|
665,563
|
$
|
410,512
|
||||
Right of use assets obtained in exchange for new operating lease liabilities
|
$
|
2,092,878
|
$
|
-
|
The accompanying notes are an integral part of these financial statements.
5
BROOKLYN IMMUNOTHERAPEUTICS, LLC
NOTES TO FINANCIAL STATEMENTS
NOTE 1 |
ORGANIZATION AND DESCRIPTION OF BUSINESS OPERATIONS
|
Brooklyn ImmunoTherapeutics LLC (“Brooklyn” or the “Company”) is a limited liability company formed under the laws of the State of Delaware on September 27, 2018, in order to complete the
acquisition of substantially all of the assets of IRX Therapeutic Inc. (“IRX”). Brooklyn operates as a clinical stage biopharmaceutical company focused on developing a cytokine-based therapy to treat patients with cancer.
NTN Buzztime, Inc. Transaction
On August 12, 2020, the Company and NTN Buzztime, Inc. (“NTN”) and BIT Merger Sub, Inc. (the “Merger Sub”), a wholly owned subsidiary of NTN, entered into an Agreement and Plan of Merger and
Reorganization (the “Merger Agreement”). Pursuant to the Merger Agreement, among other matters, the Merger Sub merged with and into Brooklyn, with Brooklyn continuing as a wholly owned subsidiary of NTN and the surviving company of the merger. The
merger was closed on March 25, 2021. After the merger, NTN changed its name to Brooklyn ImmunoTherapeutics, Inc. The merger was accounted for as a reverse acquisition with Brooklyn being deemed the acquiring company for accounting purposes.
On March 26, 2021, the Company sold its rights, title and interest in and to the assets relating to the business it operated prior to the Merger, which was operated under the name NTN Buzztime,
Inc. to eGames.com Holdings LLC (“eGames.com”) in accordance with the terms of an asset purchase agreement dated September 18, 2020, as amended, between NTN and eGames.com (the “Asset Purchase Agreement”) (See Note 4).
NOTE 2 |
LIQUIDITY AND CAPITAL RESOURCES
|
The accompanying financial statements have been prepared assuming that it will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and
commitments in the normal course of business. The financial statements do not reflect any adjustments relating to the recoverability and reclassification of assets and liabilities that might be necessary if the Company is unable to continue as a
going concern. The Company has incurred significant operating losses and has an accumulated deficit as a result of ongoing efforts to develop product candidates, including conducting clinical trials and providing general and administrative support
for these operations. As of December 31, 2020, the Company had a cash balance of $1,630,455 and an accumulated deficit of $37,380,741 (inclusive of a non-cash loss of $19,240,000 relating to change in fair value of contingent consideration). During
the year ended December 31, 2020, the Company incurred a net loss of $26,531,061 (inclusive of a non-cash loss of $19,240,000 relating to change in fair value of contingent consideration) and used cash in operations of $8,100,344. Net cash used in
operating activities during the year ended December 31, 2019 was $9,800,291.
During 2020, the Company received $4,358,750 cash proceeds from the sale of members’ equity and $309,905 in proceeds from a PPP loan payable (defined in Note 3).
The Company believes the combination of its existing cash resources, $10,500,000 contractual commitments from certain beneficial holders of Brooklyn’s Class
A membership interests (see Note 4) and sale of the Company’s common stock under the Purchase Agreement with Lincoln Park Capital Fund, LLC (“Lincoln Park”) (see Note 17) are sufficient to fund its current operating plan for at least the next 12
months from April 30, 2021.
6
BROOKLYN IMMUNOTHERAPEUTICS, LLC
NOTES TO FINANCIAL STATEMENTS
NOTE 3 |
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
|
Basis of Presentation
The financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to GAAP as
found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”).
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect (a) the reported amounts of assets and liabilities; (b) disclosure
of contingent assets and liabilities at the date of the financial statements; (c) the reported amounts of revenues and expenses during the reporting period and (d) the reported amount of the fair value of assets acquired in connection with the
business combination. Actual results could differ from those estimates. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets and the valuation of stock-based compensation.
Paycheck Protection Program Loan
On March 27, 2020, President Trump signed into law the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”), as amended on June 5, 2020 by the Paycheck Protection Program (“PPP”).
The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carry back periods, and alternative minimum tax credit refunds, modifications
to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. On May 4, 2020, the Company was granted a loan (the “Loan”) from Silicon Valley Bank in the aggregate amount of
$309,905, pursuant to the PPP under Division A, Title I of the CARES Act. The Company is continuing to evaluate and examine the impact the CARES Act may have on the business, results of operations, financial condition, or liquidity.
The Loan, which was in the form of a note dated May 4, 2020 issued by the Company, matures on May 4, 2022, and bears interest at a rate of 1% per annum.
In order to qualify for loan forgiveness, funds from the Loan may only be used for payroll costs, rent and utilities. Under the terms of the PPP, certain amounts of the Loan may be forgiven if they
are used for qualifying expenses as described in the CARES Act. The Company intends to comply with the loan forgiveness provisions in the legislation; however, there can be no assurance that the Company will obtain full forgiveness of the loans based
on the legislation.
Cash and Cash Equivalents
The Company classifies highly liquid investments with a remaining contractual maturity at date of purchase of three months or less as cash equivalents. The Company had no cash equivalents as of
December 31, 2020 and 2019.
7
BROOKLYN IMMUNOTHERAPEUTICS, LLC
NOTES TO FINANCIAL STATEMENTS
NOTE 3 |
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
|
Restricted cash
The Company had an agreement to maintain cash balances at a financial institution as collateral for a letter of credit related to the Company’s lease agreement for its office space in New York, NY,
which automatically renewed on an annual basis. In early 2020, the company replaced the letter of credit with a security deposit. Accordingly, the restricted cash was no longer required. The total amount committed under the letter of credit was
$86,000 as of December 31, 2019.
Property and Equipment
Property and equipment are recorded at cost and are depreciated over their estimated useful lives using the straight-line method. Laboratory and manufacturing equipment are depreciated over an
estimated useful life of 7 years. Leasehold improvements are depreciated over the shorter of their estimated useful life, or the lease term. Upon retirement or other disposition of these assets, the cost and related accumulated depreciation of these
assets are removed from the accounts and the resulting gain or losses are reflected in the results of operations. Expenditures for maintenance and repairs are charged to operations. Renewals and betterments are capitalized.
Goodwill
Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is not amortized but is tested for impairment
annually, or if events occur or circumstances change that would reduce the fair value of a reporting unit below its carrying value. Since management evaluates the Company as a single reporting unit, goodwill is tested for impairment at the entity
level by first performing a qualitative assessment to determine whether it is more likely than not that the fair value of the entity is less than its carrying value. If the entity does not pass the qualitative assessment, then the entity’s carrying
value is compared to its fair value. Goodwill is considered impaired if the carrying value of the entity exceeds its fair value.
In Process Research and Development
In-process research and development (“IPR&D”) assets represent the fair value assigned to technologies that were acquired on November 5, 2018 in connection with the Asset Purchase Agreement,
which have not reached technological feasibility and have no alternative future use. IPR&D assets are considered to be indefinite lived until the completion or abandonment of the associated research and development projects. During the period
that the IPR&D assets are considered indefinite-lived, they are tested for impairment on an annual basis, or more frequently if the Company becomes aware of any events occurring or changes in circumstances that indicate that the fair value of the
IPR&D assets are less than their carrying amounts. If and when development is complete, which generally occurs upon regulatory approval, and the Company is able to commercialize products associated with the IPR&D assets, these assets are then
deemed definite-lived and are amortized based on their estimated useful lives beginning at that point in time. If development is terminated or abandoned, the Company may have a full or partial impairment charge related to the IPR&D assets,
calculated as the excess of carrying value of the IPR&D assets over fair value.
8
BROOKLYN IMMUNOTHERAPEUTICS, LLC
NOTES TO FINANCIAL STATEMENTS
NOTE 3 |
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
|
Impairment of Long-Lived Assets
The Company reviews long-lived assets and certain identifiable assets for impairment whenever circumstances and situations change such that there is an indication that the carrying amounts may not
be recovered. An impairment exists when the carrying value of the long-lived asset is not recoverable and exceeds its fair value.
Research and Development
Research and development expenditures are charged to operations as incurred.
Income Taxes
The Company records deferred tax liabilities and assets based on the differences between the financial statements carrying amounts and the tax basis of assets and liabilities, using enacted tax
rates in effect in the years the differences are expected to reverse and established a valuation allowance when it was more likely than not that some portion or all of the deferred tax assets would not be realized. Income tax expense consists of the
tax payable for the period and the change during the period in deferred tax assets and liabilities.
Tax benefits from uncertain tax positions are recognized only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical
merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution. The Company has no
material uncertain tax positions for any of the reporting periods presented.
Concentration of Credit Risk
The Company maintains its cash balances in financial institutions located in the United States. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to
$250,000. At times, the Company’s cash balances may be uninsured for deposit accounts that exceed the FDIC insurance limit.
A single vendor accounted for 23% of the Company’s purchases during the year ended December 31, 2020. A different vendor accounted for 14% of the Company’s purchases during the year ended December
31, 2019. In the Company’s business, vendor concentrations could be indicative of vulnerabilities in the Company’s supply chain, which could ultimately impact the Company’s ability to continue its research and development activities.
Fair Value of Financial Instruments
Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been
established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:
• |
Level 1 Inputs – Valued based on quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.
|
9
BROOKLYN IMMUNOTHERAPEUTICS, LLC
NOTES TO FINANCIAL STATEMENTS
NOTE 3
|
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
|
Fair Value of Financial Instruments (Continued)
• |
Level 2 Inputs – Valued based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in
active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment
speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.
|
• |
Level 3 Inputs – Valued based on inputs for which there is little or no market value, which require the reporting entity to develop its own assumptions.
|
The carrying amounts reported on the balance sheet for prepaid assets and other current assets, accounts payable and accrued expenses, other current liabilities and other liabilities approximate
fair value based due to their short maturities. The carrying value of loans payable approximates its fair market value because the effective yield on this debt, which includes contractual interest rates as well as other finance charges, is comparable
to rates of returns for instruments of similar credit risk.
Leases
For the fiscal year 2020 the Company recorded monthly rental expense on a straight-line basis based on the total amount of the payments due over the lease term in accordance with GAAP. The
difference between rental expense recorded and the amount paid is credited or charged to deferred rent, which is included in accrued expenses in the accompanying balance sheet.
The Company adopted ASC 842, Leases on December 31, 2020. As such, the Company implemented new accounting policies and recognized assets and liabilities
for leases with lease terms greater than twelve months in the statement of financial position. Refer to Note 7 - Leases for a description of the accounting policies.
Commitment and Contingencies
The Company follows ASC No.450-20, Loss Contingencies, to report accounting for contingencies. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties
and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated.
Equity Based Compensation
Compensation expense for equity-based awards granted to employees is based on the estimated grant-date fair value of the award and is recognized ratably over the vesting period.
Subsequent Events
Management has evaluated subsequent events to determine if events or transactions occurring through April 30, 2021, the date on which the financial
statements were available to be issued, require potential adjustment to or disclosure in the Company’s financial statements.
10
BROOKLYN IMMUNOTHERAPEUTICS, LLC
NOTES TO FINANCIAL STATEMENTS
NOTE 3 |
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
|
Recent Accounting Standards
Early adoption is permitted. The Company is in the process of evaluating the impact of this new guidance on its financial statements and related disclosures.
In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820) Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. ASU 2018-13 resulted in
certain modifications to fair value measurement disclosures, primarily related to level 3 fair value measurements. This standard was effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019, and
early adoption was permitted. The adoption of this ASU did not have a material impact on the financial statements and related disclosures.
In February 2016, the FASB issued ASU 2016-02, Leases, which will require most leases (with the exception of leases with terms of less than one year) to be recognized on the balance sheet as a
right-of-use asset and a lease liability. Leases will be classified as operating or financing. Operating leases are expensed using the straight-line method whereas financing leases will be treated similarly to a capital lease under the current
standard. The new standard ASU 2016-02 is effective for fiscal years and interim periods, within those fiscal years, beginning after December 15, 2019 and interim periods within fiscal years beginning after December 15, 2020, but early adoption is
permitted. In July 2018, the FASB issued ASU No. 2018-11, Leases (Topic 842): Targeted Improvements which allows entities to initially apply the new leases standard at the adoption date and recognize a cumulative-effect adjustment to the opening
balance of retained earnings in the period of adoption. ASU 2016-02 also requires expanded financial statement disclosures on leasing activities. These changes will become effective for the Company for fiscal years beginning after December 15, 2020,
and interim periods within fiscal years beginning after December 15, 2021. This ASU was adopted by the Company as of December 31, 2020 resulting in the Company recording ROU assets (as defined in Note 7 - Leases) and lease liabilities on the balance
sheet. For the impact on the Company’s financial statements, refer to Note 7 - Leases.
The Company has reviewed other recent accounting standards and concluded they are either not applicable to the business or no material effect is expected on the financial statements as a result of
future adoption.
NOTE 4
|
NTN BUZZTIME, INC TRANSACTION
|
Merger Agreement with NTN Buzztime, Inc.
On August 12, 2020, the Company, NTN and the Merger Sub, entered into the Merger Agreement. The merger closed on March 25, 2021. After the merger, NTN Buzztime, Inc. changed its name to Brooklyn
ImmunoTherapeutics, Inc. The merger was accounted for as a reverse acquisition with Brooklyn being deemed the acquiring company for accounting purposes. Brooklyn, as the accounting acquirer, recorded the assets acquired and liabilities assumed of NTN
in the merger at their fair values as of the acquisition date. The combined company will trade on the NYSE American under the ticker symbol “BTX”.
Brooklyn was determined to be the accounting acquirer based upon the terms of the Merger and other factors including (i) Brooklyn members and Maxim Group LLC, Brooklyn’s financial adviser (the
“Financial Adviser”) received 96.37% of NTN’s outstanding common stock on a fully diluted basis immediately following the effective
11
BROOKLYN IMMUNOTHERAPEUTICS, LLC
NOTES TO FINANCIAL STATEMENTS
NOTE 4
|
NTN BUZZTIME, INC TRANSACTION (Continued)
|
Merger Agreement with NTN Buzztime, Inc. (Continued)
time of the merger, (ii) Brooklyn will hold all of the board seats of the combined company and (iii) Brooklyn’s management will hold all key positions in the management of the combined company.
At the closing of the merger, all of the outstanding membership interests of Brooklyn converted into the right to receive shares of NTN’s common stock equal to the exchange ratio of 1-for-2.
Brooklyn exchanged all of their equity interests in Brooklyn for an aggregate of 39,999,760 shares of common stock, of which 1,067,879 shares were issued as compensation to the Financial Adviser for its services to Brooklyn in connection with the
merger.
Disposition
On March 26, 2021, the Company sold its rights, title and interest in and to the assets relating to the business operated by NTN prior to the Merger to eGames.com in exchange for a payment of a
purchase price of $2,000,000 and assumption of specified liabilities relating to the NTN business. The sale was completed in accordance with the terms of the Asset Purchase Agreement.
Rights Offering
The Company is obligated under the Merger Agreement to have $10,000,000 in cash and cash equivalents on its balance sheet at the effective time of the merger
(the “Required Funds”). To ensure that the Company has the Required Funds, certain beneficial holders of Brooklyn’s Class A membership interests have entered into contractual commitments to invest $10,000,000 into Brooklyn immediately prior to the
closing of the merger with NTN. During March 2021 the Company offered to its Class A unit holders an additional 5% rights offering, a total amount of $500,000 was raised by this right offering. Funding to the rights offering was received between
February 17 and April 5, 2021.
NOTE 5 |
FAIR VALUE OF FINANCIAL INSTRUMENTS
|
Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been
established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:
• |
Level 1 Inputs – Valued based on quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.
|
• |
Level 2 Inputs – Valued based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in
active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment
speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.
|
• |
Level 3 Inputs – Valued based on inputs for which there is little or no market value, which require the reporting entity to develop its own assumptions.
|
12
BROOKLYN IMMUNOTHERAPEUTICS, LLC
NOTES TO FINANCIAL STATEMENTS
NOTE 5
|
FAIR VALUE OF FINANCIAL INSTRUMENTS (Continued)
|
The following tables summarize the liabilities that are measured at fair value as of December 31, 2020 and December 31, 2019:
December 31, 2020
|
||||||||||||
Description
|
Level 1
|
Level 2
|
Level 3
|
|||||||||
Liabilities:
|
||||||||||||
Contigent consideration
|
-
|
-
|
20,110,000
|
|||||||||
Total
|
$
|
-
|
$
|
-
|
$
|
20,110,000
|
December 31, 2019
|
||||||||||||
Description
|
Level 1
|
Level 2
|
Level 3
|
|||||||||
Liabilities:
|
||||||||||||
Contigent consideration
|
-
|
-
|
870,000
|
|||||||||
Total
|
$
|
-
|
$
|
-
|
$
|
870,000
|
Contingent consideration has initially been valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third-party valuation services or other market
observable data. The third-party valuation services utilize industry standard valuation models, including discounted cash flow analysis to determine value. After completing its validation procedures, the Company adjusted the fair value carrying
amount as of December 31, 2020. The contingent consideration is resultant to the Asset Purchase Agreement with IRX entered by Brooklyn for the acquisition of substantially all of the net assets of IRX, according to which, Brooklyn is obligated to pay
royalties to certain noteholders and shareholders of IRX based on future revenues from any future IRX-2 product sales. The fair value of the contingent consideration has been estimated using the discounted cash flow method of the income approach.
The following table reflects the activity for the Company’s contingent consideration liabilities measured at fair value using Level 3 inputs for the year ended December 31, 2020:
Other Liabilities:
Contingent
Consideration
|
||||
Balance at December 31, 2019
|
$
|
870,000
|
||
Fair value adjustments included in operating expenses
|
19,240,000
|
|||
Balance at December 31, 2020
|
$
|
20,110,000
|
13
BROOKLYN IMMUNOTHERAPEUTICS, LLC
NOTES TO FINANCIAL STATEMENTS
NOTE 5 |
FAIR VALUE OF FINANCIAL INSTRUMENTS (Continued)
|
Contingent consideration is measured at fair value and is based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The
valuation of contingent consideration uses assumptions the Company believes would be made by a market participant. The Company assesses these estimates on an on-going basis as additional data impacting the assumptions is obtained. Future changes in
the fair value of contingent consideration related to updated assumptions and estimates are recognized within the statements of operations.
Contingent consideration may change significantly as development progresses and additional data are obtained, impacting the Company’s assumptions regarding probabilities of successful achievement
of related milestone used to estimate the fair value of the liability and the timing in which they are expected to be achieved. In evaluating the fair value information, considerable judgment is required to interpret the market data used to develop
the estimates. The estimates of fair value may not be indicative of the amounts that could be realized in a current market exchange. Accordingly, the use of different market assumptions and/or different valuation techniques could result in
materially different fair value estimates.
Changes in the fair value measurement each period reflect the passage of time as well as the impact of adjustments, if any, to the likelihood of achieving the specified targets. Contingent
consideration is recorded in the balance sheets in long- term liabilities. During the year ended December 31, 2020, the Company recorded a $19,240,000 loss on fair value remeasurement of contingent consideration, primarily due to changes in
discount rates, passage of time and updated assumptions.
For purposes of this calculation, a royalty equal to 13% of revenue (consisting of the royalty due to University of South Florida and the royalty due to the collaborator) is assumed until 2029 and
a royalty of 7% of revenues is assumed from 2030 to 2038. The post patent decline is 50% in the first year and 10% thereafter. Income taxes were projected to be 26% of net Company royalty savings. The cash flows were discounted by the liability
specific weighted average cost of capital of 24% using the mid-point convention.
NOTE 6 |
PROPERTY AND EQUIPMENT
|
Property and equipment consist of the following:
December 31,
|
||||||||
2020
|
2019
|
|||||||
Laboratory and manufacturing equipment
|
$
|
299,839
|
$
|
261,164
|
||||
Leasehold improvements
|
414,504
|
414,504
|
||||||
714,343
|
675,668
|
|||||||
Less: accumulated depreciation and amortization
|
(120,237
|
)
|
(21,905
|
)
|
||||
Property and equipment, net
|
$
|
594,106
|
$
|
653,763
|
Depreciation expense charged to operations during the year ended December 31, 2020 was $98,332. Depreciation expense charged to operations was $20,407 during the year ended December 31, 2019.
No depreciation expense is recorded on fixed assets in process until such time as the assets are completed and are placed into service. These fixed assets in process were placed into service on
February 14, 2020.
14
BROOKLYN IMMUNOTHERAPEUTICS, LLC
NOTES TO FINANCIAL STATEMENTS
NOTE 7 |
LEASES
|
The Company adopted ASC 842, Leases on December 31, 2020 using the modified transition method without retrospective application to comparative periods. The Company elected the package of three
practical expedients allowed for under the transition guidance. Accordingly, the Company did not reassess: (1) whether any expired or existing contracts are/or contain leases; (2) the lease classification for any expired or existing leases; or (3)
initial direct costs for any existing leases. The Company has also elected not to recognize right of use assets (“ROU assets”) and lease liabilities for short-term leases that have a term of 12 months or less.
The Company’s material operating leases consist of corporate office, as well as laboratory space. The office space is situated at 654 Madison Ave in New York, NY and expires on November 30, 2026.
The laboratory space situated in Brooklyn, New York. Effective on July 1, 2019, the laboratory lease was amended to increase the space rented under the laboratory lease, rent increases 3% on January 1 of each lease year. The laboratory lease expires
on December 31, 2025. Our leases have remaining terms of 5 - 6 years. Brooklyn determines if an arrangement meets the criteria of a lease at inception, at which time it also performs an analysis to determine whether the lease qualifies as operating
or financing. The Company does not currently have any finance leases.
Upon adoption, the Company recorded approximately $2,092,878 of ROU assets and $2,178,612 of lease liabilities related to operating leases in the balance sheet. At transition, the ROU assets were
measured at the initial amount of the lease liability adjusted for any deferred rent and cease-use liabilities. The Company also recognized a $91,846 cumulative-effect adjustment to retained earnings related to the deferred loss on sublease. This
loss was previously amortized to rent expense in the statements of operations. Since the Company has a full valuation allowance against its deferred tax assets, the impact is a reduction to our deferred tax assets and related valuation allowance,
which resulted in no tax impact to the net change to equity.
Operating lease liabilities represent the present value of lease payments not yet paid. ROU assets represent Brooklyn’s right to use an underlying asset and are based upon the operating lease
liabilities adjusted for prepaid or accrued lease payments, initial direct costs, lease incentives and impairment of operating lease assets. As the rate implicit in the lease is not readily determinable, the Company used its incremental borrowing
rates based on the information available at the lease commencement date in determining the present value of lease payments. To determine the present value of lease payments not yet paid, the Company estimates secured borrowing rates corresponding to
the maturities of the leases.
The Company has elected the practical expedient to not separate non-lease components from the lease components to which they relate and instead account for each as a single lease component, for all
underlying asset classes. Some leasing arrangements require variable payments that are dependent on usage or may vary for other reasons, such as payments for insurance, tax payments and other miscellaneous costs. The variable portion of lease
payments is not included in the ROU assets or lease liabilities. Rather, variable payments, other than those dependent upon an index or rate, are expensed when the obligation for those payments is incurred and are included in lease expenses.
Accordingly, all expenses associated with a lease contract are accounted for as lease expenses.
Operating leases are included in right of use assets - operating leases and operating lease liabilities, current and long-term, in the balance sheet. Lease expense for operating leases is
recognized on a straight-line basis over the lease term and is included in selling, administrative and other operating costs in the statements of operations.
15
BROOKLYN IMMUNOTHERAPEUTICS, LLC
NOTES TO FINANCIAL STATEMENTS
NOTE 7 |
LEASES (Continued)
|
In accordance with provisions of ASC 842 Leases (“ASC 842”), we treated the sublease as a separate lease as we were not relieved of the primary obligation under the original lease. We continue to
account for the original Manhattan facility, as a lessee, in the same manner as prior to the commencement date of the sublease. We accounted for the sublease as a lessor of the lease. We classified the sublease as an operating lease as it did not
meet the criteria of a Sale-Type or Direct Financing lease.
We recognize operating lease expense and lease payments from the sublease, on a straight-line basis, in our statements of operations over the lease terms. During the year ended December 31, 2020,
our net operating lease expenses are as follows:
Year ended
December 31, 2020
|
||||
Operating lease expense
|
$
|
591,272
|
||
Sublease income
|
(77,164
|
)
|
||
Variable lease expense
|
20,945
|
|||
Total
|
$
|
535,053
|
The table below provides supplemental information related to operating leases for the year ended:
Year ended
December 31, 2020
|
||||
Cash paid within operating cash flow
|
$
|
584,690
|
||
Weighted average remaining lease term (years)
|
5.5
|
|||
Weighted average discount rate
|
14.5
|
%
|
Maturities of operating lease liabilities as of December 31, 2020:
For the years ending
December 31,
|
Amount
|
|||
2021 |
$
|
571,470
|
||
2022
|
588,918
|
|||
2023
|
621,793
|
|||
2024
|
624,172
|
|||
2025
|
641,981
|
|||
Thereafter |
105,674
|
|||
Future lease payments
|
3,154,008
|
|||
Less: Imputed interest
|
960,468
|
|||
Total operating lease liabilities
|
$
|
2,193,540
|
16
BROOKLYN IMMUNOTHERAPEUTICS, LLC
NOTES TO FINANCIAL STATEMENTS
NOTE 7 |
LEASES (Continued)
|
The Company recorded rent expense on a straight-line basis over the term of the lease. Rent expense charged to operations was $544,214 during the year ended December 31, 2019, which is included in
general and administrative expenses in the accompanying statements of operations.
Sublease Agreement
On April 18, 2019, the Company entered into a sublease agreement with Nezu Asia Capital Management, LLC (“the Tenant”), whereby the Tenant agreed to sublease approximately 999 square feet of space
currently rented by the Company in New York, NY, for an initial term of 8 years, commencing on May 15, 2019. The term of the sublease expires on October 31, 2026 with no option to extend the sublease term. Rent payments provided by the Tenant under
the sublease agreement began on September 1, 2019. The sublease agreement stipulates an annual rent increase of 2.25%. The Tenant also is responsible for paying to the Company all tenant energy costs, annual operating costs, and annual tax costs
attributable to the subleased space during the term of the sublease.
Future lease payments as of December 31, 2020 from our sublease agreement are as follows:
For the years ending
December 31,
|
Amount
|
|||
2021 |
$
|
80,682
|
||
2022 |
82,419
|
|||
2023 |
84,194
|
|||
2024 |
86,010
|
|||
2025 |
87,867
|
|||
Thereafter |
74,590
|
|||
Total
|
$
|
495,762
|
The Company received sublease payments $32,676 during the year ended December 31, 2019, respectively. In connection with the sublease, the Company recognized a lease liability of $103,350 at
December 31, 2019.
NOTE 8 |
GOODWILL AND IN PROCESS RESEARCH AND DEVELOPMENT
|
The Company recorded Goodwill and IPR&D in the amount of $2,043,747 and $6,860,000, respectively, in connection with the acquisition of IRX. IPR&D assets are considered to be indefinite
lived until the completion or abandonment of the associated research and development projects.
NOTE 9 |
SECURITY DEPOSITS AND OTHER ASSETS
|
On January 24, 2020, the Company replaced the letter of credit held for lease property 654 Madison Avenue with a security deposit of $84,915.
On February 9, 2017, a retainer in the amount of $300,401 to a service provider was paid, pursuant to a master services agreement (the “Master Services Agreement”) which expires in 2022. The
retainer represented 10% of the amount of estimated direct costs expected to be incurred by the service provider, in connection with clinical development services provided under the Master Services Agreement.
17
BROOKLYN IMMUNOTHERAPEUTICS, LLC
NOTES TO FINANCIAL STATEMENTS
NOTE 9 |
SECURITY DEPOSITS AND OTHER ASSETS (Continued)
|
On June 14, 2018, a security deposit was paid in the amount of $63,220 pursuant to a lease agreement which expires on December 28, 2025.
NOTE 10 |
ACCRUED EXPENSES
|
Accrued expenses consist of the following:
December 31,
|
||||||||
2020
|
2019
|
|||||||
Compensation payable
|
$
|
293,535
|
$
|
540,513
|
||||
Accrued general and administrative expenses
|
207,468
|
94,265
|
||||||
Accrued research and development expenses
|
399,892
|
695,551
|
||||||
Accrued interest
|
150,125
|
90,512
|
||||||
Loss on legal settlement
|
-
|
100,000
|
||||||
Total accrued expenses
|
$
|
1,051,020
|
$
|
1,520,841
|
NOTE 11 |
INVESTOR DEPOSITS
|
Investor deposits of $0 and $665,563 at December 31, 2020 and 2019, respectively, represents funding of capital commitments in excess of capital calls.
NOTE 12 |
LOANS PAYABLE
|
In connection with the acquisition of IRX the Company assumed certain notes payable (“IRX Notes”) in the amount of $410,000. On January 27, 2020, the IRX Notes were amended to extend the maturity
date to the earlier of (i) a change of control, as defined, or (ii) December 31, 2021.
NOTE 13 |
COMMITMENTS AND CONTINGENCIES
|
The Company is involved in litigation and arbitrations from time to time in the ordinary course of business. Legal fees and other costs associated with such actions are expensed as incurred. In
addition, the Company assesses, in conjunction with its legal counsel, the need to record a liability for litigation and contingencies. The Company reserves for costs relating to these matters when a loss is probable, and the amount can be reasonably
estimated.
University of South Florida
As of December 31, 2019, the Company was involved in a legal matter with the University of South Florida (“USF”), whereby USF sent a demand letter to IRX and Brooklyn on December 21, 2018,
contending its right to 25% of IRX proceeds from the business combination. The Company entered into a settlement agreement with USF on August 7, 2020. The amount of $150,000 was paid on August 19, 2020. Other than the royalty payments described
below, no other amounts are due to USF under the license agreement.
18
BROOKLYN IMMUNOTHERAPEUTICS, LLC
NOTES TO FINANCIAL STATEMENTS
NOTE 13 |
COMMITMENTS AND CONTINGENCIES (Continued)
|
Litigation
The pre-merger entity, NTN Buzztime, Inc. and its former directors were named as defendants in ten substantially similar actions brought by purported stockholders of ours arising out of the
Merger: Henson v. NTN Buzztime, Inc., No. 1:20-cv-08663-LGS (S.D.N.Y. filed Oct. 16, 2020); Monsour v. NTN Buzztime, Inc., No. 1:20-cv-08755-LGS (S.D.N.Y. filed Oct.
20, 2020); Amanfo v. NTN Buzztime, Inc., No. 1:20-cv-08747-LGS (S.D.N.Y. filed Oct. 20, 2020); Carlson v. NTN Buzztime, Inc., No. 1:21-cv-00047-LGS (S.D.N.Y. filed
Jan. 4, 2021); Finger v. NTN Buzztime, Inc., No. 1:21-cv-00728-LGS (S.D.N.Y. filed Jan. 26, 2021); Falikman v. NTN Buzztime, Inc., No. 1:20-cv-05106-EK-SJB (E.D.N.Y.
filed Oct. 23, 2020); Haas v. NTN Buzztime, Inc., No. 3:20-cv-02123-BAS-JLB (S.D. Cal. Oct. 29, 2020); Gallo v. NTN Buzztime, Inc., No. 3:21-cv-00157-WQH-AGS (S.D.
Cal. filed Jan. 28, 2021); Chinta v. NTN Buzztime, Inc., No. 1:20-cv-01401-CFC (D. Del. filed Oct. 16, 2020); and Nicosia v. NTN Buzztime, Inc., No. 1:21-cv-00125-CFC
(D. Del. filed Jan. 30, 2021 ) (collectively, the “Stockholder Actions”). NTN Buzztime, Inc. also was named as a defendant in two of the actions (Chinta and Nicosia). The Stockholder Actions assert claims
asserting violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 and Rule 14a-9 promulgated thereunder. Henson and Monsour assert additional
claims for breach of fiduciary duty. The complaints allege that defendants failed to disclose allegedly material information in the Form S-4 Registration Statement filed with the SEC on October 2, 2020, including (1) certain details regarding any
projections or forecasts NTN Buzztime, Inc. or Brooklyn may have made, and the analyses performed by our financial advisor, Newbridge Securities Corporation; (2) conflicts concerning the sales process; and (3) disclosures regarding whether or not we
entered into any confidentiality agreements with standstill and/or “don’t ask, don’t waive” provisions. The complaints allege that these purported failures to disclose rendered the Form S-4 false and misleading. The complaints request a preliminary
and permanent injunction of the Merger; rescission of the Merger if executed and/or rescissory damages in unspecified amounts; direction to the individual directors to disseminate a compliant Registration Statement; an accounting by us for all
alleged damages suffered; a declaration that certain federal securities laws have been violated; and costs, including attorneys’ and expert fees and expenses. Process was served in Henson, Chinta, Amanfo, Falikman, Carlson and Gallo,
but not in any of the other Stockholder Actions. Although plaintiffs request injunctive relief in their complaints, they have not filed motions for such relief.
NTN Buzztime, Inc. and its former directors deny any wrongdoing or liability with respect to the allegations and claims asserted, or which could have been asserted, in the Stockholder Actions, as
they believed the disclosures set forth in the Form S-4 complied fully with applicable law. Nevertheless, in order to avoid nuisance, potential expense and delay, and to provide additional information to its stockholders, NTN Buzztime, Inc.
determined to voluntarily supplement the Form S-4 with further disclosures (the “Supplemental Disclosures”) on Form 8-K, which was filed with the SEC on February 26, 2021. These Supplemental Disclosures discussed, inter
alia, (1) certain details regarding any projections or forecasts NTN or Brooklyn may have made, and the analyses performed by our financial advisor, Newbridge Securities Corporation; and (2) information regarding whether or not NTN entered
into any confidentiality agreements with standstill and/or “don’t ask, don’t waive” provisions. As a consequence of the issuance of the Supplemental Disclosures all claims asserted in the Stockholder Actions have been rendered moot and have requested
that all plaintiffs in the Stockholder Actions dismiss their claims voluntarily (or immediately inform NTN or the Company if they are not willing to do so). Since the issuance of the Supplemental Disclosures, the plaintiffs in Henson, Chinta, Monsour, Amanfo, Carlson and
Nicosia have voluntarily dismissed their cases. NTN expects the plaintiffs in the other Stockholder Actions to do the same. On March 2, 2021, the court in Haas issued
an order to show cause why the case should not be dismissed for failure to prosecute. Plaintiffs in the Stockholder Actions reserve the right to seek payment by us to their attorneys of a “mootness fee” in an amount yet to be determined in connection
with the issuance of the Supplemental Disclosures.
19
BROOKLYN IMMUNOTHERAPEUTICS, LLC
NOTES TO FINANCIAL STATEMENTS
NOTE 13 |
COMMITMENTS AND CONTINGENCIES (Continued)
|
Litigation (Continued)
The Company denies the allegations asserted against the Company and intends to oppose the suit in which it is named vigorously.
Licensing Agreements
University of South Florida
The Company has license agreements with USF, granting the Company the right to sell, market, and distribute IRX-2, subject to a 7% royalty payable to USF based on a percentage of gross product
sales. Under the license agreement with USF, the Company is obligated to repay patent prosecution expenses incurred by USF. To date, the Company has not recorded any product sales, or obligations related to USF patent prosecution expenses. The
license agreement terminates upon the expiration of the IRX-2 patents.
Novellus
In December 2020 (and as amended in April 2021), Brooklyn entered into option agreements with Novellus Therapeutics Limited and Factor Bioscience Limited (together, “Novellus”) to obtain the right to
exclusively license Novellus’ IP and mRNA cell reprogramming and gene editing technology for use in the development of certain cell-based therapies to treat cancer and rare blood disorders, such as sickle cell disease and beta thalassemia.
The option is exercisable before May 21, 2021 and requires Brooklyn to pay a non-refundable option fee of $500,000 (even if the option
is not exercised). Brooklyn paid an advance on the license fees owed of $1 million on April 13, 2021, for an extension of the option until May 21, 2021.
The license agreement is currently being negotiated which include the following material terms:
|
•
|
Brooklyn will pay an upfront payment of $4 million (inclusive of the $500,000 option fee) and receive an exclusive license (with right to
sublicense) to Novellus’ patents, including know-how and any improvements, for developing and commercializing certain cell-based therapies. As discussed above Brooklyn already paid an advance of $1 million of the license fee on April 13,
2021. In addition the Company paid $1,500,000 on April 29, 2021.
|
|
•
|
Upon payment of additional milestones of $5 million (within 6 months of signing) and $7 million (within 18 months of signing), Brooklyn will have
the ability to acquire additional cell lines for developing cell-based therapies in cancer and rare blood disorders.
|
20
BROOKLYN IMMUNOTHERAPEUTICS, LLC
NOTES TO FINANCIAL STATEMENTS
NOTE 13 |
COMMITMENTS AND CONTINGENCIES (Continued)
|
Royalty Agreements
Collaborator Royalty Agreement
Effective June 22, 2018, IRX terminated its Research, Development and Option Facilitation Agreement and its Options Agreement (the “RDO and Options Agreements”) with a collaborative partner (the
“Collaborator”), pursuant to a termination agreement (the “Termination Agreement”). In connection with the Termination Agreement, all of the rights granted to the Collaborator under the RDO and Options Agreements were terminated, and the IRX has no
obligation to refund any payments received from the Collaborator. As consideration for entering into the Termination Agreement, the Collaborator will receive a royalty equal to 6% of revenues from the sale of IRX-2, for the period of time beginning
with the first sale of IRX-2 through the later of (i) the twelfth anniversary of the first sale of IRX-2, or (ii) the expiration of the last IRX patent, or other exclusivity of IRX-2.
Investor Royalty Agreement
On March 22, 2021, Brooklyn restated its royalty agreement with the former Class A membership investors of the GP and LP (the “Investor Royalty Agreement”), whereby such beneficial holders will
continue to receive royalties in an aggregate amount equal to 4% of the net revenues of the Company.
The Company has not recognized any revenues to date, and no royalties are due pursuant to the any of the above-mentioned royalty agreements.
On July 8, 2020, the Brooklyn entered into a retention agreement (the “Retention Agreement”) with an employee (the “Employee”). Pursuant to the Retention Agreement, the Employee will continue full
performance as an employee to Brooklyn through January 8, 2021 (the “Initial Retention Agreement”) for which, subject to certain conditions, the Employee will be a lump sum of $200,000 in the second quarter of 2021.
In addition, the Company may unilaterally elect a second retention period from January 8, 2021 to July 8, 2021 (the “Second Retention Period”). Should the Company do so, subject to certain
conditions, the Employee will be eligible for another payment of $200,000 in the third quarter of 2021.
NOTE 14 |
STOCK-BASED COMPENSATION
|
During the period from November 6, 2018 through December 31, 2018, the Company granted 4,125 of restricted common units to certain employees valued at $88.75 per unit, or an aggregate of $366,094.
On September 23, 2019, the company granted 125 restricted common units valued at $88.75 per unit, or $11,094, to a single employee. The units vest 25% on the first anniversary of the date of grant, and the remainder vest monthly over the following
three years.
The Company measures employee stock-based awards at grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the award.
The Company recorded stock-based compensation expense of $90,936 during the year ended December 31, 2020 and recognized $91,689 during the year ended December 31, 2019, related to the amortization
of the restricted common units, which is included in general and administrative expenses on the accompanying statements of operations.
21
BROOKLYN IMMUNOTHERAPEUTICS, LLC
NOTES TO FINANCIAL STATEMENTS
NOTE 14 |
STOCK-BASED COMPENSATION (Continued)
|
The following table sets forth stock option activity for the year ended December 31, 2020:
Number of Options
|
Weighted Average
Exercise Price ($)
|
Weighted Average
Remaining
Contractual Life
(in months)
|
||||||||||
Outstanding at January 1, 2020
|
2,932
|
88.75
|
35
|
|||||||||
Granted
|
-
|
-
|
-
|
|||||||||
Vested
|
(1,025
|
)
|
88.75
|
-
|
||||||||
Forfeited
|
-
|
-
|
-
|
|||||||||
Outstanding at December 31, 2020
|
1,907
|
88.75
|
23
|
|||||||||
Vested and exercisable as at December 31, 2020
|
2,230
|
88.75
|
As of December 31, 2020, the unrecognized compensation cost related to 1,907 unvested stock options expected to vest was $169,246. This unrecognized compensation will be recognized over and
estimated weighted average amortization period of 1 year and 11 months. There were no options granted or exercised during the year ended December 31, 2020.
The following table sets forth stock option activity for the year ended December 31, 2019:
Number of Options
|
Weighted Average
Exercise Price ($)
|
Weighted Average
Remaining
Contractual Life
(in months)
|
||||||||||
Outstanding at January 1, 2019
|
3,953
|
88.75
|
46
|
|||||||||
Granted
|
125
|
88.75
|
48
|
|||||||||
Vested
|
(1,033
|
)
|
88.75
|
-
|
||||||||
Forfeited
|
(113
|
)
|
88.75
|
-
|
||||||||
Outstanding at December 31, 2019
|
2,932
|
88.75
|
35
|
|||||||||
Vested and exercisable as at December 31, 2019
|
1,205
|
88.75
|
22
BROOKLYN IMMUNOTHERAPEUTICS, LLC
NOTES TO FINANCIAL STATEMENTS
NOTE 15 |
MEMBERS’ EQUITY
|
During the year ended December 31, 2020, the Company made capital calls in the aggregate amount of $5,024,313 in exchange for Class A Units. The Company received cash
of $4,358,750 and applied investor deposits of $665,563 in satisfaction of capital calls made during 2019.
During the year ended December 31, 2019, the Company made capital calls in the aggregate amount of $8,218,762 in exchange for Class A Units. The Company received cash of $7,808,250 and applied
investor deposits of $410,512 in satisfaction of capital calls made during 2019. Further, the Company received cash of $665,563 representing payments in excess of capital calls during the years ended December 31, 2019, which was recorded in other
current liabilities on the accompanying balance sheet.
NOTE 16 |
INCOME TAX
|
The Company is a limited liability company treated as a partnership for federal and state income tax purposes, and the taxable income or loss is passed through to its members. The Company is
subject to the Unincorporated Business Tax (“UBT”) on taxable income attributable to New York City. As of December 31, 2020, the Company has an operating loss carry forward of $18,675,525 available to offset future taxable income, which does not
expire.
The Company files its Federal, New York State, and New York City returns. The Federal, New York State, and New York City returns for the 2018 through 2020 tax years remain open to examination. The
Company is not currently undergoing any tax audit and has not received notice of an audit. The Company tax benefits for the year December 31, 2020 and 2019 result from increases in the gross deferred tax assets and are offset by a corresponding tax
expense due to an increase in the valuation allowance associated with those same deferred tax assets, resulting in an effective tax rate of 0%.
On March 27, 2020, the CARES Act was enacted in response to COVID-19 pandemic. Under ASC 740, the effects of changes in tax rates and laws are recognized in the period which the new legislation is
enacted. The CARES Act made various tax law changes including among other things (i) increasing the limitation under Section 163(j) of the Internal Revenue Code of 1986, as amended (the “IRC”) for 2019 and 2020 to permit additional expensing of
interest and (ii) enacting a technical correction so that qualified improvement property can be immediately expensed under IRC Section 168(k). The Company determined there was no impact to income taxes.
The income tax provision consists of the following:
December 31,
|
||||||||
2020
|
2019
|
|||||||
Federal:
|
||||||||
Current
|
$
|
-
|
$
|
-
|
||||
Deferred
|
-
|
-
|
||||||
State:
|
||||||||
Current
|
-
|
-
|
||||||
Deferred
|
322,221
|
357,482
|
||||||
322,221
|
357,482
|
|||||||
Change in valuation allowance
|
(322,221
|
)
|
(357,482
|
)
|
||||
Income tax benefit (provision)
|
$
|
-
|
$
|
-
|
23
BROOKLYN IMMUNOTHERAPEUTICS, LLC
NOTES TO FINANCIAL STATEMENTS
NOTE 16 |
INCOME TAX (Continued)
|
Deferred tax assets and liabilities consist of the effects of temporary differences as shown in the table below. Deferred tax assets have been fully reserved by a valuation allowance since it is
more likely than not that such tax benefits will not be realized.
December 31,
|
||||||||
2020
|
2019
|
|||||||
Deferred tax assets:
|
||||||||
Net operating loss carryforward
|
$
|
747,021
|
$
|
424,800
|
||||
Less: Valuation allowance
|
(747,021
|
)
|
(424,800
|
)
|
||||
Total
|
$
|
-
|
$
|
-
|
NOTE 17 |
SUBSEQUENT EVENTS
|
The Company has evaluated subsequent events from the balance sheet date through April 30, 2021.
From time to time, the Company is subject to legal proceedings in the ordinary course of business. While management presently believes that the ultimate outcome of these proceedings, individually
and in the aggregate, will not materially harm its financial position, cash flows, or overall trends in results of operations, legal proceedings are subject to inherent uncertainties, and unfavorable rulings or outcomes could occur that have,
individually or in the aggregate, a material adverse effect on the Company’s business, financial condition or operating results. The Company is not currently subject to any pending material legal proceedings except as described below.
Lawsuit
On or about February 5, 2021, Dhesh Govender, a former short-term consultant of Brooklyn, filed a complaint against Brooklyn and certain individuals that plaintiff alleges are directors of
Brooklyn. The complaint is captioned, Dhesh Govender v. Brooklyn ImmunoTherapeutics, LLC, et al., Index No. 650847/2021 (N.Y. Sup. Ct. N.Y. Cty. 2021). Plaintiff purports to state claims against Brooklyn and the individual defendants under the New
York State Executive Law, New York State Administrative Code and other statutory and common law claims for alleged unlawful and discriminatory conduct based on race, national origin, and hostile work environment. Plaintiff also asserts various breach
of contract, fraud, and quantum meruit claims based on an alleged oral agreement pursuant to which he alleges Brooklyn agreed to hire him as an executive once Brooklyn went public. To date, plaintiff has not effected service of the complaint.
Brooklyn believes that the claims asserted in the complaint have no merit and intends to vigorously defend the suit, once properly served.
Merger Approval and Effective Date
The proposed transaction was approved during a special stockholder meeting on March 15, 2021 and the merger closed on March 25, 2021. The sale of NTN’s business was effective March 26, 2021 (See
Note 4).
24
BROOKLYN IMMUNOTHERAPEUTICS, LLC
NOTES TO FINANCIAL STATEMENTS
NOTE 17 |
SUBSEQUENT EVENTS (Continued)
|
Private Placement Offerings
The Company and Lincoln Park is in the process of negotiating a (i) a purchase agreement (the “Purchase Agreement”); and (ii) a registration rights agreement (the “Registration Rights Agreement”).
Pursuant to the Purchase Agreement, Lincoln Park will purchase, and the Company will sell, upon the terms and subject conditions stated therein an aggregate of 1,379,668 shares of common stock.
Under the terms and subject to the conditions of the Purchase Agreement, the Company will have the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park will be obligated to
purchase up to $20,000,000 in the aggregate of shares of common stock. Sales of common stock by the Company, if any, will be subject to certain limitations, and may occur from time to time, at the Company’s sole discretion.
Following the commencement date, under the Purchase Agreement, on any business day selected by the Company, the Company may direct Lincoln Park to purchase up to 60,000 shares of common stock on
such business day (each, a “Regular Purchase”), provided, however, that (i) the Regular Purchase may be increased to up to 80,000 shares, provided that the closing sale price of the common stock is not below $5.50 on the purchase date; and (ii) the
Regular Purchase may be increased to up to 120,000 shares, provided that the closing sale price of the common stock is not below $7.00 on the purchase date. In each case, Lincoln Park’s maximum commitment in any single Regular Purchase may not exceed
$1,000,000. The purchase price per share for each such Regular Purchase will be based off of prevailing market prices of common stock immediately preceding the time of sale. In addition to Regular Purchases, the Company may direct Lincoln Park to
purchase other amounts as accelerated purchases or as additional accelerated purchases if the closing sale price of the common stock exceeds certain threshold prices as set forth in the Purchase Agreement. In all instances, the Company may not sell
shares of its common stock to Lincoln Park under the Purchase Agreement if it would result in Lincoln Park beneficially owning more than 19.99% of the outstanding shares of common stock.
The Company will enter into an agreement with Lincoln Park that it will not enter into any “variable rate” transactions with any third party for a period defined in the Purchase Agreement. The
Company will have the right to terminate the Purchase Agreement at any time, at no cost or penalty.
Actual sales of shares of common stock to Lincoln Park under the Purchase Agreement will depend on a variety of factors to be determined by the Company from time to time, including, among others,
market conditions, the trading price of the common stock and determinations by the Company as to the appropriate sources of funding for the Company and its operations. The Company expects that any net proceeds received by the Company from such sales
to Lincoln Park will be used for research and development, working capital and general corporate purposes.
The Purchase Agreement, and the Registration Rights Agreement may contain customary representations, warranties, agreements, and conditions to completing future sale transactions, indemnification
rights and obligations of the parties.
Related Party
Upon the appointment of Dr. Federoff, he was granted a nonqualified stock option covering 2,627,915 shares of Brooklyn’s common stock (the “Time-Based Option “).
The Time-Based Option will have a per share exercise price equal to the closing price of a share of Brooklyn’s common stock on the NYSE American Stock Exchange on April 16, 2021.
Of the shares covered by the Time-Based Option, 656,979 will vest on April 16, 2022, 54,748 will vest on the sixteenth day of each month from May 2022 through March 2025, and the remaining 54,756 will vest on April 16, 2025, in each case for so
long as the Dr. Federoff provides continuous service to Brooklyn through the relevant vesting date.
Additionally, on April 16, 2021, Dr. Federoff was granted a nonqualified stock option covering 597,253 shares of Brooklyn’s common stock (the “Milestone Option”). The Milestone Option will have
a per share exercise price equal to the closing price of a share of Brooklyn ’ s common stock on the NYSE American Stock Exchange on April 16, 2021. The Milestone Option will fully vest upon the first concurrence by the US Food and Drug
Administration that a proposed investigation may proceed following review of a BTX filed investigational new drug application in connection with that certain license among Brooklyn, Factor Biosciences Therapeutics Limited and Novellus Therapeutics
Limited. This milestone is subject to Dr. Federoff’s continuous service with Brooklyn through such vesting date.
The unvested portion of the Time-Based Option and the Milestone Option will terminate upon the termination of Dr. Federoff’s employment with Brooklyn for any reason, subject to certain vesting
acceleration provisions upon a qualifying termination, as described in his employment agreement with Brooklyn. Unless earlier terminated in accordance with their terms, each of the Time-Based Option and the Milestone Option will otherwise expire on
the 10th anniversary of their respective grant date and be subject to the terms and conditions of the respective option agreement approved by Brooklyn. Each of the Time-Based Option and the Milestone Option is intended to constitute an “employment
inducement grant” in accordance with the employment inducement grant rules set forth in Section 711(a) of the NYSE American LLC Company Guide, and is offered as an inducement material to Dr. Federoff in connection with Brooklyn’s hiring of Dr.
Federoff and will be granted outside of Brooklyn’s shareholder-approved equity compensation plans.
25
Exhibit 99.2
BROOKLYN IMMUNOTHERAPEUTICS, LLC
FINANCIAL STATEMENTS
Year ended December 31, 2019 and periods from November 6, 2018 through December 31, 2018
and January 1, 2018 through November 5, 2018
Table of Contents
Page
|
|
Report of Independent Registered Public Accounting Firm
|
2
|
Balance Sheets
|
3
|
Statements of Operations
|
4
|
Statements of Changes in Stockholders’ Deficiency and Members’ Equity
|
5
|
Statements of Cash Flows
|
6
|
Notes to Financial Statements
|
7
|
1
BROOKLYN IMMUNOTHERAPEUTICS, LLC
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Members and Board of Managers of Brooklyn ImmunoTherapeutics, LLC
Opinion on the Financial Statements
We have audited the accompanying balance sheets of Brooklyn ImmunoTherapeutics, LLC (Successor) and IRX Therapeutics, Inc. (Predecessor) (the “Company”) as of December 31, 2019 and 2018, and the
related statements of operations, stockholders’ equity/members’ equity and cash flows for the year ended December 31, 2019 and for the period of November 6, 2018 through December 31, 2018 (Successor), and the period from January 1, 2018 through
November 5, 2018 (Predecessor), and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December
31, 2019 and 2018, and the results of its operations and its cash flows for the year ended December 31, 2019 and for the period of November 6, 2018 through December 31, 2018 (Successor), and the period from January 1, 2018 through November 5, 2018
(Predecessor), in conformity with accounting principles generally accepted in the United States of America.
Explanatory Paragraph – Going Concern
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 2, the Company has incurred significant losses
and needs to raise additional funds to meet its obligations and sustain its operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also
described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit. We are a public
accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and
regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we
plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its
internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal
control over financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those
risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management,
as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
/s/ Marcum LLP
We are uncertain as to the year we began serving consecutively as the auditor of the Company’s financial statements; however, we are aware that we have been the Company’s auditor consecutively
since at least 2013.
New York, NY
April 24, 2020
2
BALANCE SHEETS
December 31,
|
||||||||
2019
|
2018
|
|||||||
Assets
|
||||||||
Current Assets:
|
||||||||
Cash
|
$
|
5,014,819
|
$
|
6,325,431
|
||||
Subscriptions receivable
|
-
|
850,000
|
||||||
Prepaid expenses and other current assets
|
86,668
|
19,998
|
||||||
Total Current Assets
|
5,101,487
|
7,195,429
|
||||||
Restricted cash
|
86,000
|
86,000
|
||||||
Property and equipment, net
|
653,763
|
68,099
|
||||||
Goodwill
|
2,043,747
|
2,043,747
|
||||||
In process research and development
|
6,860,000
|
6,860,000
|
||||||
Security deposits and other assets
|
363,621
|
379,331
|
||||||
Total Assets
|
$
|
15,108,618
|
$
|
16,632,606
|
||||
Liabilities and Members’ Equity
|
||||||||
Current Liabilities:
|
||||||||
Accounts payable
|
$
|
1,735,610
|
$
|
2,647,532
|
||||
Accrued expenses
|
1,520,841
|
1,696,793
|
||||||
Investor deposits
|
665,563
|
638,575
|
||||||
Loans payable
|
410,000
|
410,000
|
||||||
Current portion of lease liability
|
4,026
|
-
|
||||||
Total Current Liabilities
|
4,336,040
|
5,392,900
|
||||||
Lease liability, non-current
|
99,030
|
-
|
||||||
Other liabilities
|
930,445
|
870,000
|
||||||
Total Liabilities
|
5,365,515
|
6,262,900
|
||||||
Commitments and Contingencies
|
||||||||
Members’ Equity:
|
||||||||
Class A membership units
|
18,177,692
|
9,958,930
|
||||||
Class B membership units
|
1,400,000
|
1,400,000
|
||||||
Class C membership units
|
1,000,000
|
1,000,000
|
||||||
Common units
|
106,937
|
15,248
|
||||||
Accumulated deficit
|
(10,941,526
|
)
|
(2,004,472
|
)
|
||||
Total Members’ Equity
|
9,743,103
|
10,369,706
|
||||||
Total Liabilities and Members’ Equity
|
$
|
15,108,618
|
$
|
16,632,606
|
The accompanying notes are an integral part of these financial statements.
3
STATEMENTS OF OPERATIONS
Successor
|
Predecessor
|
|||||||||||
For the Year Ended
December 31, 2019
|
For the period from
November 6, 2018
through
December 31, 2018
|
For the period from
January 1, 2018
through
November 5, 2018
|
||||||||||
Operating Expenses
|
||||||||||||
General and administrative
|
$
|
3,721,490
|
$
|
374,267
|
$
|
5,351,698
|
||||||
Research and development
|
5,156,266
|
1,621,084
|
9,078,193
|
|||||||||
Total Operating Expenses
|
8,877,756
|
1,995,351
|
14,429,891
|
|||||||||
Loss From Operations
|
(8,877,756
|
)
|
(1,995,351
|
)
|
(14,429,891
|
)
|
||||||
Other Expenses
|
||||||||||||
Interest expense, net
|
(59,298
|
)
|
(9,121
|
)
|
(1,668,711
|
)
|
||||||
Total Expenses
|
(59,298
|
)
|
(9,121
|
)
|
(1,668,711
|
)
|
||||||
Net Loss
|
$
|
(8,937,054
|
)
|
$
|
(2,004,472
|
)
|
(16,098,602
|
)
|
||||
Deemed dividends on preferred stock
|
(685,892
|
)
|
||||||||||
Gain on extinguishment of preferred stock.
|
106,560,811
|
|||||||||||
Net income attributable to common stockholders
|
$
|
89,776,317
|
The accompanying notes are an integral part of these financial statements.
4
STATEMENT OF CHANGES IN STOCKHOLDERS’ DEFICIENCY AND MEMBERS’ EQUITY
Predecessor
|
Preferred Stock
|
Additional
Paid-In
Capital
|
Subscriptions
Receivable,
Related
Parties
|
Accumulated
Deficit
|
Total
Stockholders’
Deficiency
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Series D
|
Series C
|
Series B
|
Series A
|
Common Stock
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Shares
|
Amount
|
Shares
|
Amount
|
Shares
|
Amount
|
|||||||||||||||||||||||||||||||||||||||||||||||
Balance - January 1, 2018
|
35,400,669
|
$
|
35,400
|
40,460,713
|
$
|
40,461
|
35,016
|
$
|
35
|
140,639
|
$
|
141
|
7,968,224
|
$
|
7,968
|
$
|
179,148,961
|
$
|
(88,663
|
)
|
$
|
(187,130,857
|
)
|
$
|
(7,986,554
|
)
|
||||||||||||||||||||||||||||||
Issuance of common stock upon exchange of preferred stock
|
-
|
-
|
(40,460,713
|
)
|
(40,461
|
)
|
(35,016
|
)
|
(35
|
)
|
(140,639
|
)
|
(141
|
)
|
16,771,866
|
16,772
|
(106,536,946
|
)
|
-
|
106,560,811
|
-
|
|||||||||||||||||||||||||||||||||||
Net loss
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(16,098,602
|
)
|
(16,098,602
|
)
|
||||||||||||||||||||||||||||||||||||||||
Balance - November 5, 2018
|
35,400,669
|
$
|
35,400
|
-
|
$
|
-
|
-
|
$
|
-
|
-
|
$
|
-
|
24,740,090
|
$
|
24,740
|
$
|
72,612,015
|
$
|
(88,663
|
)
|
$
|
(96,668,648
|
)
|
$
|
(24,085,156
|
)
|
Successor
|
Membership Equity
|
Accumulated
Deficit
|
Total
Members’
Equity
|
|||||||||||||||||||||
Class A
|
Class B
|
Class C
|
Common
|
|||||||||||||||||||||
Balance - November 6, 2018
|
$
|
6,482,005
|
$
|
-
|
$
|
-
|
$
|
-
|
$
|
-
|
$
|
6,482,005
|
||||||||||||
Stock based compensation:
|
||||||||||||||||||||||||
Amortization of restricted common units
|
-
|
-
|
-
|
15,248
|
-
|
15,248
|
||||||||||||||||||
Issuance of membership units for purchase of IRX
|
-
|
1,400,000
|
1,000,000
|
-
|
-
|
2,400,000
|
||||||||||||||||||
Membership units issued in exchange for services
|
5,000
|
-
|
-
|
-
|
-
|
5,000
|
||||||||||||||||||
Sale of members’ equity
|
1,955,579
|
-
|
-
|
-
|
-
|
1,955,579
|
||||||||||||||||||
Members’ equity exchanged for loans payable and interest
|
1,516,346
|
-
|
-
|
-
|
-
|
1,516,346
|
||||||||||||||||||
Net loss
|
-
|
-
|
-
|
-
|
(2,004,472
|
)
|
(2,004,472
|
)
|
||||||||||||||||
Balance - January 1, 2019
|
9,958,930
|
1,400,000
|
1,000,000
|
15,248
|
(2,004,472
|
)
|
10,369,706
|
|||||||||||||||||
Stock based compensation:
|
||||||||||||||||||||||||
Amortization of restricted common units
|
-
|
-
|
-
|
91,689
|
-
|
91,689
|
||||||||||||||||||
Sale of members’ equity
|
8,218,762
|
-
|
-
|
-
|
-
|
8,218,762
|
||||||||||||||||||
Net loss
|
-
|
-
|
-
|
-
|
(8,937,054
|
)
|
(8,937,054
|
)
|
||||||||||||||||
Balance - December 31, 2019
|
$
|
18,177,692
|
$
|
1,400,000
|
$
|
1,000,000
|
$
|
106,937
|
$
|
(10,941,526
|
)
|
$
|
9,743,103
|
The accompanying notes are an integral part of these financial statements.
5
STATEMENTS OF CASH FLOWS
Successor
|
Predecessor
|
|||||||||||
For the Year
Ended
December 31, 2019
|
For the Period
from November 6,
2018 through
December 31, 2018
|
For the Period
from January 1,
2018 through
November 5, 2018
|
||||||||||
Cash Flows from Operating Activities
|
||||||||||||
Net loss
|
$
|
(8,937,054
|
)
|
$
|
(2,004,472
|
)
|
$
|
(16,098,602
|
)
|
|||
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||||||
Depreciation and amortization
|
20,407
|
1,498
|
136,314
|
|||||||||
Equity compensation
|
91,689
|
20,248
|
-
|
|||||||||
Loss on operating sublease
|
103,350
|
-
|
-
|
|||||||||
Change in operating assets and liabilities:
|
||||||||||||
Prepaid expenses and other current assets
|
(66,670
|
)
|
-
|
(69,099
|
)
|
|||||||
Security deposits
|
76,155
|
-
|
8,001
|
|||||||||
Accounts payable and accrued expenses
|
(1,087,874
|
)
|
(168,298
|
)
|
(300,034
|
)
|
||||||
Lease liability
|
(294
|
)
|
||||||||||
Other liabilities
|
-
|
-
|
37,727
|
|||||||||
Total adjustments
|
(863,237
|
)
|
(146,552
|
)
|
(187,091
|
)
|
||||||
Net Cash Used in Operating Activities
|
(9,800,291
|
)
|
(2,151,024
|
)
|
(16,285,693
|
)
|
||||||
Cash Flows from Investing Activities
|
||||||||||||
Patent costs
|
-
|
-
|
(172,196
|
)
|
||||||||
Purchase of property and equipment
|
(606,071
|
)
|
-
|
(76,485
|
)
|
|||||||
Purchase of IRX - cash and restricted cash acquired
|
-
|
336,296
|
-
|
|||||||||
Net Cash Provided by (Used in) Investing Activities
|
(606,071
|
)
|
336,296
|
(248,681
|
)
|
|||||||
Cash Flows from Financing Activities
|
||||||||||||
Proceeds from loans payable
|
-
|
-
|
3,394,226
|
|||||||||
Proceeds from loans payable, related parties
|
-
|
-
|
1,500,000
|
|||||||||
Proceeds from convertible debt
|
-
|
-
|
11,803,321
|
|||||||||
Proceeds from investor deposits
|
437,500
|
-
|
-
|
|||||||||
Proceeds from the collection of subscriptions receivable
|
850,000
|
-
|
-
|
|||||||||
Proceeds from sale of members’ equity
|
7,808,250
|
1,744,154
|
-
|
|||||||||
Net Cash Provided by Financing Activities
|
9,095,750
|
1,744,154
|
16,697,547
|
|||||||||
Net (Decrease) Increase in Cash
|
(1,310,612
|
)
|
(70,574
|
)
|
163,173
|
|||||||
Cash and Restricted Cash - Beginning of Period
|
6,411,431
|
6,482,005
|
173,123
|
|||||||||
Cash and Restricted Cash - End of Period
|
$
|
5,100,819
|
$
|
6,411,431
|
$
|
336,296
|
||||||
Cash and Restricted Cash consisted of the following:
|
||||||||||||
Cash
|
$
|
5,014,819
|
$
|
6,325,431
|
$
|
250,296
|
||||||
Restricted cash
|
86,000
|
86,000
|
86,000
|
|||||||||
$
|
5,100,819
|
$
|
6,411,431
|
$
|
336,296
|
|||||||
Supplemental Disclosures of Cash Flow Information:
|
||||||||||||
Cash paid during the period for:
|
||||||||||||
Interest
|
$
|
-
|
$
|
-
|
$
|
-
|
||||||
Income taxes
|
$
|
-
|
$
|
-
|
$
|
-
|
||||||
Non-cash investing and financing activities:
|
||||||||||||
Investor deposits for sale of members’ equity
|
$
|
410,512
|
$
|
-
|
$
|
-
|
||||||
Conversion of loans payable and interest into members’ equity
|
$
|
-
|
$
|
1,516,346
|
$
|
-
|
||||||
Exchange of Series A, B and C preferred stock for common stock
|
$
|
-
|
$
|
-
|
$
|
106,560,811
|
||||||
Purchase of the assets and liabilities of IRX:
|
||||||||||||
Assets acquired and liabilities assumed:
|
||||||||||||
Cash acquired
|
$
|
-
|
$
|
336,296
|
$
|
-
|
||||||
Prepaid expenses and other current assets
|
-
|
19,998
|
-
|
|||||||||
Security deposits and other assets
|
-
|
379,331
|
-
|
|||||||||
Goodwill
|
-
|
2,043,747
|
-
|
|||||||||
In-process R&D
|
-
|
6,860,000
|
-
|
|||||||||
Property and equipment
|
-
|
69,597
|
-
|
|||||||||
Accounts payable and accrued expenses
|
-
|
(4,528,969
|
)
|
-
|
||||||||
Loans payable, related parties
|
-
|
(1,500,000
|
)
|
-
|
||||||||
Loans payable
|
-
|
(410,000
|
)
|
-
|
||||||||
Total purchase price
|
$
|
-
|
$
|
3,270,000
|
$
|
-
|
||||||
Purchase price consisted of:
|
||||||||||||
Members’ equity issued to acquire the asset and liabilities of IRX
|
-
|
2,400,000
|
-
|
|||||||||
Contingent consideration
|
-
|
870,000
|
-
|
|||||||||
Total purchase price
|
$
|
-
|
$
|
3,270,000
|
$
|
-
|
The accompanying notes are an integral part of these financial statements.
6
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2019 AND
THE PERIODS FROM NOVEMBER 6, 2018 THROUGH DECEMBER 31, 2018 (SUCCESSOR PERIOD)
AND FROM JANUARY 1, 2018 THROUGH NOVEMBER 5, 2018 (PREDECESSOR PERIOD)
NOTE 1 DESCRIPTION OF BUSINESS
Brooklyn ImmunoTherapeutics LLC (“BITX” or the “Successor”) is a limited liability company formed under the laws of the State of Delaware on September 27, 2018, for the purpose of consummating a
business combination with IRX Therapeutics, Inc. (“IRX” or the “Predecessor”). The Predecessor and Successor are together referred to herein as the “Company”. On November 6, 2018, (the “Closing Date”) pursuant to an Asset Purchase Agreement with
IRX, BITX acquired substantially all of the assets of IRX (the “Business Combination”). Subsequent to the Business Combination, BITX operates as a clinical stage biopharmaceutical company focused on developing a cytokine-based therapy to treat
patients with cancer. BITX had no operations prior to the Business Combination.
NOTE 2 GOING CONCERN
Going Concern
The accompanying financial statements have been prepared assuming that the Successor will continue as a going concern. As discussed below, the Company has sustained losses from operations and has
an accumulated deficit. These conditions raise substantial doubt about the Successor’s ability to continue as a going concern for the next twelve months from the date on which the financial statements were available to be issued. Management’s plans
in regard to these matters are also described below. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
As of December 31, 2019, the Company had a cash balance of $5,014,819 and an accumulated deficit of $10,941,526. During the year ended December 31, 2019, the Company incurred a net loss of
$8,937,054 and used cash in operations of $9,800,291. Net cash used in operating activities during the year ended December 31, 2018 was $18,436,717 (including $16,285,693 during the Predecessor period).
During 2019, the Company received $7,808,250 cash proceeds from the sale of members’ equity, $437,500 in proceeds from investor deposits, and $850,000 in proceeds from the collection of
subscription receivable. As of December 31, 2019, the Company expects to receive additional cash for capital call commitments of $3,858,750 (see Note 14 – Subsequent Events). The Company expects to have ongoing needs for significant working capital
in order to fund research and development activities and expects to either (a) enter into a strategic transaction with a third party; (b) license its products to other companies for certain applications, or (c) raise additional funds through equity
or debt financing. However, there can be no assurance that the Company will be successful in entering into a strategic transaction or securing additional capital. If the Company is unsuccessful in raising capital, the Company might (a) initiate
cost reductions; (b) forego research and development opportunities; (c) seek extensions of time to fund its liabilities or (d) seek protection from creditors.
NOTE 3 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).
The Company’s financial statement presentation distinguishes a “Predecessor” for the periods prior to the Closing Date and a “Successor” for the periods following (and including) the Closing Date.
The operating results of IRX for the period January 1, 2018 through November 5, 2018 are presented for the Predecessor period in the accompanying consolidated financial statements. The financial position and operating results of the BITX as of
December 31, 2019 and 2018 and for the year ended December 31, 2019 and the period from November 6, 2018 through December 31, 2018 are presented for the Successor period in the accompanying financial statements.
The Predecessor’s significant accounting policies are substantially the same as those of the Successor presented below.
7
BROOKLYN IMMUNOTHERAPEUTICS, LLC
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2019 AND
THE PERIODS FROM NOVEMBER 6, 2018 THROUGH DECEMBER 31, 2018 (SUCCESSOR PERIOD)
AND FROM JANUARY 1, 2018 THROUGH NOVEMBER 5, 2018 (PREDECESSOR PERIOD)
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect (a) the reported amounts of assets and liabilities; (b)
disclosure of contingent assets and liabilities at the date of the financial statements; (c) the reported amounts of revenues and expenses during the reporting period and (d) the reported amount of the fair value of assets acquired in connection
with the business combination. Actual results could differ from those estimates. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets and the valuation of stock-based compensation.
Cash and Cash Equivalents
The Company classifies highly liquid investments with a remaining contractual maturity at date of purchase of three months or less as cash equivalents. The Company had no cash equivalents as of
December 31, 2019 and 2018.
Restricted Cash
The Company has an agreement to maintain cash balances at a financial institution as collateral for a letter of credit related to the Company’s lease agreement for its office space in New York, NY,
which automatically renews on an annual basis. The total amount committed under the letter of credit is $86,000 as of December 31, 2019 and 2018.
Property and Equipment
Property and equipment are recorded at cost and are depreciated over their estimated useful lives using the straight-line method. Laboratory and manufacturing equipment are depreciated over an
estimated useful life of 7 years. Leasehold improvements are depreciated over the shorter of their estimated useful life, or the lease term. Upon retirement or other disposition of these assets, the cost and related accumulated depreciation of
these assets are removed from the accounts and the resulting gain or losses are reflected in the results of operations. Expenditures for maintenance and repairs are charged to operations. Renewals and betterments are capitalized.
Goodwill
Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is not amortized but is tested for impairment
annually, or if events occur or circumstances change that would reduce the fair value of a reporting unit below its carrying value. Since management evaluates the Company as a single reporting unit, goodwill is tested for impairment at the entity
level by first performing a qualitative assessment to determine whether it is more likely than not that the fair value of the entity is less than its carrying value. If the entity does not pass the qualitative assessment, then the entity’s carrying
value is compared to its fair value. Goodwill is considered impaired if the carrying value of the entity exceeds its fair value.
In Process Research and Development
In-process research and development (“IPR&D”) assets represent the fair value assigned to technologies that were acquired on November 5, 2018 in connection with the Asset Purchase Agreement,
which have not reached technological feasibility and have no alternative future use. IPR&D assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development projects. During the period
that the IPR&D assets are considered indefinite-lived, they are tested for impairment on an annual basis, or more frequently if the Successor becomes aware of any events occurring or changes in circumstances that indicate that the fair value of
the IPR&D assets are less than their carrying amounts. If and when development is complete, which generally occurs upon regulatory approval, and the Successor is able to commercialize products associated with the IPR&D assets, these assets
are then deemed definite-lived and are amortized based on their estimated useful lives beginning at that point in time. If development is terminated or abandoned, the Successor may have a full or partial impairment charge related to the IPR&D
assets, calculated as the excess of carrying value of the IPR&D assets over fair value.
8
BROOKLYN IMMUNOTHERAPEUTICS, LLC
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2019 AND
THE PERIODS FROM NOVEMBER 6, 2018 THROUGH DECEMBER 31, 2018 (SUCCESSOR PERIOD)
AND FROM JANUARY 1, 2018 THROUGH NOVEMBER 5, 2018 (PREDECESSOR PERIOD)
Impairment of Long-Lived Assets
The Company reviews long-lived assets and certain identifiable assets for impairment whenever circumstances and situations change such that there is an indication that the carrying amounts may not
be recovered. An impairment exists when the carrying value of the long-lived asset is not recoverable and exceeds its fair value.
Research and Development
Research and development expenditures are charged to operations as incurred.
Income Taxes
The Company is not subject to U.S. federal, state, and income taxes for the Successor period, since all of its income or losses are passed through to its members. Taxable income attributable to New
York City during the year ended December 31, 2019 and the period from November 6, 2018 through December 31, 2018 is subject to the New York City Unincorporated Business Tax. During the Predecessor period, the Company was subject to corporate income
taxes in the U.S. Federal jurisdiction, the state of New York and New York City.
The Company records deferred tax liabilities and assets based on the differences between the financial statement carrying amounts and the tax basis of assets and liabilities, using enacted tax
rates in effect in the years the differences are expected to reverse and established a valuation allowance when it was more likely than not that some portion or all of the deferred tax assets would not be realized. Income tax expense consists of
the tax payable for the period and the change during the period in deferred tax assets and liabilities.
Tax benefits from uncertain tax positions are recognized only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical
merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution. The Company has no
material uncertain tax positions for any of the reporting periods presented.
Concentration of Credit Risk
The Company maintains its cash balances in financial institutions located in the United States. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to
$250,000. At times, the Company’s cash balances may be uninsured for deposit accounts that exceed the Federal Deposit Insurance Corporation (“FDIC”) insurance limit.
A single vendor accounted for 14.0% of the Company’s purchases during the year ended December 31, 2019. A different vendor accounted for 11% of the Company’s purchases during the year ended
December 31, 2018. In the Company’s business, vendor concentrations could be indicative of vulnerabilities in the Company’s supply chain, which could ultimately impact the Company’s ability to continue its research and development activities.
Fair Value of Financial Instruments
Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been
established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:
|
●
|
Level 1 Inputs – Valued based on quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.
|
●
|
Level 2 Inputs – Valued based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for
similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest
rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.
|
●
|
Level 3 Inputs – Valued based on inputs for which there is little or no market value, which require the reporting entity to develop its own assumptions.
|
9
BROOKLYN IMMUNOTHERAPEUTICS, LLC
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2019 AND
THE PERIODS FROM NOVEMBER 6, 2018 THROUGH DECEMBER 31, 2018 (SUCCESSOR PERIOD)
AND FROM JANUARY 1, 2018 THROUGH NOVEMBER 5, 2018 (PREDECESSOR PERIOD)
The carrying amounts reported on the balance sheet for prepaid assets and other current assets, accounts payable and accrued expenses, other current liabilities and other liabilities approximate
fair value based due to their short maturities. The carrying value of loans payable approximates its fair market value because the effective yield on this debt, which includes contractual interest rates as well as other finance charges, is
comparable to rates of returns for instruments of similar credit risk.
Leases
The Company records straight-line monthly rental expense based on the total amount of the payments due over the lease term in accordance with U.S. GAAP. The difference between rental expense
recorded and the amount paid is credited or charged to deferred rent, which is included in accrued expenses in the accompanying balance sheets (see Note 11 - Commitments and Contingencies, Sublease Agreement).
Commitment and Contingencies
The Company follows Accounting Standards Codification (“ASC”) No.450-20 (“ASC 450-20”), Loss Contingencies, to report accounting for contingencies.
Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated.
Equity Based Compensation
Compensation expense for equity-based awards granted to employees is based on the estimated grant-date fair value of the award and is recognized ratably over the vesting period.
Subsequent Events
Management has evaluated subsequent events to determine if events or transactions occurring through April 24, 2020, the date on which the financial statements were available to be issued, require
potential adjustment to or disclosure in the Company’s financial statements.
NOTE 4 BUSINESS COMBINATION
On November 6, 2018, BITX entered into an Asset Purchase Agreement with IRX, whereby BITX acquired substantially all of the net assets of IRX. Under the Asset Purchase Agreement, BITX is also
obligated to pay royalties based on future revenues to certain former shareholders of IRX. The estimated fair value of future royalty payments at the date of the Business Combination was $870,000, which is accounted for as contingent consideration
and is reflected in other liabilities on the accompanying balance sheet. The fair value of the contingent consideration was estimated using the discounted cash flow method of the income approach.
The aggregate consideration for the purchase of the IRX assets was $3,270,000, which consisted $2,400,000 equal to the fair value of the membership units issued to the former shareholders and debt
holders of IRX and $870,000 equal to the fair value of contingent consideration.
The following table details the allocation of the purchase price for the acquisition of BITX:
Cash
|
$
|
250,296
|
||
Restricted cash
|
86,000
|
|||
Prepaid expenses and other current assets
|
19,998
|
|||
Security deposits and other assets
|
379,331
|
|||
Laboratory equipment
|
69,597
|
|||
In process research and development
|
6,860,000
|
|||
Accounts payable and accrued expenses
|
(4,528,969
|
)
|
||
Loans payable
|
(410,000
|
)
|
||
Loans payable, related parties
|
(1,500,000
|
)
|
||
Net fair value assigned to assets acquired and liabilities assumed
|
1,226,253
|
|||
Goodwill
|
2,043,747
|
|||
Total
|
$
|
3,270,000
|
10
BROOKLYN IMMUNOTHERAPEUTICS, LLC
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2019 AND
THE PERIODS FROM NOVEMBER 6, 2018 THROUGH DECEMBER 31, 2018 (SUCCESSOR PERIOD)
AND FROM JANUARY 1, 2018 THROUGH NOVEMBER 5, 2018 (PREDECESSOR PERIOD)
The fair value of the in-process research and development was determined using the “relief-from-royalty” method of income approach. The purchase price in excess of the tangible and identifiable
assets acquired, less liabilities assumed, is recognized as goodwill.
Goodwill arising from the business combination mainly consisted of the assets acquired by BITX subject to the liabilities assumed from IRX. The goodwill represents the excess consideration paid
over the fair value of the asset acquired and liabilities, and BITX paid a premium to gain control of the assists and the potential future upside of those assets. BITX’s goodwill is not deductible for tax purposes. Further, BITX’s goodwill and
intangible assets are subject to a test for impairment on an annual basis (or on a quarterly basis as appropriate).
NOTE 5 PROPERTY AND EQUIPMENT
Property and equipment consist of the following:
December 31,
|
||||||||
2019
|
2018
|
|||||||
Laboratory and manufacturing equipment
|
$
|
261,164
|
$
|
69,597
|
||||
Leasehold improvements
|
414,504
|
-
|
||||||
675,668
|
69,597
|
|||||||
Less: accumulated depreciation and amortization
|
(21,905
|
)
|
(1,498
|
)
|
||||
Property and equipment, net
|
$
|
653,763
|
$
|
68,099
|
Depreciation expense charged to operations during the year ended December 31, 2019 was $20,407. Depreciation expense charged to operations was $1,498 and $6,888 and during the periods from November
6, 2018 through December 31, 2018 and from January 1, 2018 through November 5, 2018, respectively.
As of December 31, 2019, the Company has $64,461 of leasehold improvements that had not yet been placed into service. No depreciation expense is recorded on fixed assets in process until such time
as the assets are completed and are placed into service. These fixed assets in process were placed into service on February 14, 2020.
NOTE 6 GOODWILL AND IN PROCESS RESEARCH AND DEVELOPMENT
The Company recorded Goodwill and IPR&D in the amount of $2,043,747 and $6,860,000, respectively, in connection with the Business Combination (see Note 4 – Business Combination). IPR&D
assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development projects.
NOTE 7 SECURITY DEPOSITS AND OTHER ASSETS
On February 9, 2017, the Predecessor paid a retainer in the amount of $300,401 to a service provider, pursuant to a Master Services Agreement which expires on October 23, 2020. The retainer
represented 10% of the amount of estimated direct costs expected to be incurred by the service provider, in connection with clinical development services provided under the Master Services Agreement.
On June 14, 2018, the Predecessor paid a security deposit in the amount of $63,220 pursuant to a lease agreement which expires on December 28, 2025.
NOTE 8 ACCRUED EXPENSES
Accrued expenses consist of the following:
December 31,
|
||||||||
2019
|
2018
|
|||||||
Compensation payable
|
$
|
540,513
|
$
|
214,327
|
||||
Deferred rent payable
|
-
|
6,169
|
||||||
Accrued general and administrative expenses
|
94,265
|
62,743
|
||||||
Accrued research and development expenses
|
695,551
|
1,380,440
|
||||||
Accrued interest
|
90,512
|
33,114
|
||||||
Loss on legal settlement
|
100,000
|
-
|
||||||
Total accrued expenses
|
$
|
1,520,841
|
$
|
1,696,793
|
11
BROOKLYN IMMUNOTHERAPEUTICS, LLC
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2019 AND
THE PERIODS FROM NOVEMBER 6, 2018 THROUGH DECEMBER 31, 2018 (SUCCESSOR PERIOD)
AND FROM JANUARY 1, 2018 THROUGH NOVEMBER 5, 2018 (PREDECESSOR PERIOD)
NOTE 9 INVESTOR DEPOSITS
Investor deposits of $665,563 and $638,575 at December 31, 2019 and 2018, respectively, represents funding of capital commitments in excess of capital calls.
NOTE 10 LOANS PAYABLE AND LOANS PAYABLE TO RELATED PARTIES
During the period from January 1, 2018 through July 31, 2018, the Predecessor issued unsecured convertible promissory notes (the “Predecessor Notes”) in the aggregate amount of $19,447,996, in
exchange for which cash proceeds of $3,534,000 were received during 2017, cash proceeds of $15,165,816 were received during 2018, $716,449 represented the conversion to principal of interest payable on the note and $31,731 was issued in connection
with the CFO Separation Agreement (see Note 11 - Commitments and Contingencies). Of the total Predecessor Notes issued, Predecessor Notes in the aggregate amount of $11,095,368 were issued to members of the Predecessor’s Board of Directors. Prior
to the Business Combination, the Predecessor Notes were convertible into common stock at the noteholder’s option in connection with the sale of at least 80% of the outstanding capital stock of the Predecessor. The Predecessor Notes bear interest at
14.5% per annum and mature on December 31, 2019.
Predecessor Notes in the amount of $410,000 were assumed by the Successor in connection with the Business Combination. Interest expense related to the Predecessor Notes was $59,450 during the year
ended December 31, 2019 and was $9,121 and $1,652,466 during the period from November 6, 2018 through December 31, 2018 and the period from January 1, 2018 through November 5, 2018, respectively. On January 27, 2020, the Predecessor Notes were
amended to extend the maturity date to the earlier of (i) a change of control, as defined, or (2) December 31, 2021.
During October 2018, the Predecessor sold bridge notes in the aggregate amount of $1,500,000 to three members of the Board of Directors (the “Bridge Notes”). Interest expense in the amount of
$16,346 was incurred on the Bridge Notes during the Predecessor period. On November 6, 2018, in connection with the Business Combination, the Bridge Notes and related accrued interest were converted into Class A units of the Successor in the
aggregate amount of $1,516,346.
NOTE 11 COMMITMENTS AND CONTINGENCIES
Legal Matters
The Company is involved in litigation and arbitrations from time to time in the ordinary course of business. Legal fees and other costs associated with such actions are expensed as incurred. In
addition, the Company assesses, in conjunction with its legal counsel, the need to record a liability for litigation and contingencies. The Company reserves for costs relating to these matters when a loss is probable, and the amount can be
reasonably estimated.
As of December 31, 2019, the Company is involved in a legal matter with the University of South Florida (“USF”), whereby USF sent a demand letter to IRX and BITX on December 21, 2018, contending
its right to 25% of IRX proceeds from the Business Combination. To date, no lawsuit has been filed and the Company and USF are working to settle the matter. Pursuant to ASC 450-20, and based on consultation with legal counsel, the Company has
recorded $100,000 of accrued legal settlements representing the estimated loss related to this matter, which is recorded within general and administrative expense in the accompanying Statements of Operations. As of December 31, 2019, the potential
exposure resulting from an adverse outcome of any potential legal proceedings could exceed the recorded accrual. However, the Company does not believe that the impact of litigation, if any, will be material.
Licensing Agreements
The Company has license agreements with USF, granting the Company the right to sell, market, and distribute IRX-2, subject to a 7% royalty payable to USF based on a percentage of gross product
sales. Under the license agreement with USF, the Company is obligated to repay patent prosecution expenses incurred by USF. To date, the Company has not recorded any product sales, or obligations related to USF patent prosecution expenses. The
license agreement terminates upon the expiration of the IRX-2 patents.
12
BROOKLYN IMMUNOTHERAPEUTICS, LLC
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2019 AND
THE PERIODS FROM NOVEMBER 6, 2018 THROUGH DECEMBER 31, 2018 (SUCCESSOR PERIOD)
AND FROM JANUARY 1, 2018 THROUGH NOVEMBER 5, 2018 (PREDECESSOR PERIOD)
Royalty Agreements
Predecessor Royalty Agreements
In connection with the Business Combination, the Successor assumed the Predecessor’s obligation to pay a royalty in the aggregate amount of 1% of revenues from any future IRX-2 product sales,
pursuant to royalty agreements with certain noteholders and shareholders of the Predecessor (see Note 4 - Business Combination).
Collaborator Royalty Agreement
Effective June 28, 2018, the Predecessor terminated its Research, Development and Option Facilitation Agreement (the “RDO Agreement”) and its Options Agreement with a collaborative partner (the
“Collaborator”), pursuant to a Termination Agreement. In connection with the Termination Agreement, all of the rights granted to the Collaborator under the RDO and Option Agreements were terminated, and the Predecessor has no obligation to refund
any payments received from the Collaborator. As consideration for entering into the Termination Agreement, the Collaborator will receive a royalty equal to 6% of revenues from the sale of IRX-2, for the period of time beginning with the first sale
of IRX-2 through the later of (i) the twelfth anniversary of the first sale of IRX-2, or (ii) the expiration of the last IRX patent, or other exclusivity of IRX-2.
Investor Royalty Agreement
On November 6, 2018, the Successor entered into a royalty agreement with the Class A membership investors (the “Investor Royalty Agreement”), pursuant to which owners of Class A membership units
will receive compensatory royalties in an aggregate amount equal to 4% of the net revenues of the Successor.
The Company has not recognized any revenues to date, and no royalties are due pursuant to the any of the above-mentioned royalty agreements.
Employment Agreements
Effective July 31, 2018, the Predecessor entered into a separation agreement (the “CFO Separation Agreement”) with its former Chief Financial Officer (the “Former CFO”). Pursuant to the terms of
the Separation Agreement, the Former CFO was entitled to receive six months of severance pay equal to his current base salary of $275,000 per annum and received a Predecessor Note in the principal amount of $31,731.
On December 13, 2019, the Successor entered into a separation agreement (the “CEO Separation Agreement”) with its former Chief Executive Officer (the “Former CEO”). Pursuant to the terms of the
Separation Agreement, the Former CEO was entitled to a six months of severance pay equal to $225,000, a one-time payout of accrued but unused vacation time equal to $37,518, and continued coverage under the Company’s group health and dental
insurance plan equal to $14,032.
Operating Lease Commitments
In connection with the Business Combination, BITX assumed IRX’s lease for office space at 654 Madison Ave in New York, NY (the “Office Lease”). The Office Lease expires on November 30, 2026. The
annual rent for the first year (beginning on the date of the Business Combination) is approximately $93,275 and the rent increases annually.
In connection with the Business Combination, BITX also assumed IRX’s lease for laboratory space in Brooklyn, New York (the “Laboratory Lease”), with annual rent expense for the first year of
$314,577 beginning on the date of the Business Combination. Effective on July 1, 2019, the Laboratory Lease was amended to increase the space rented under the Laboratory Lease. Annual rent expense (including the Company’s pro rata share of
operating expenses) for 12 months beginning July 1, 2019 increased to $485,061 pursuant to the amended Laboratory Lease, and the rent increases 3% on January 1 of each lease year. The Laboratory Lease expires on December 31, 2025.
13
BROOKLYN IMMUNOTHERAPEUTICS, LLC
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2019 AND
THE PERIODS FROM NOVEMBER 6, 2018 THROUGH DECEMBER 31, 2018 (SUCCESSOR PERIOD)
AND FROM JANUARY 1, 2018 THROUGH NOVEMBER 5, 2018 (PREDECESSOR PERIOD)
Future commitments under the Successor’s operating lease are as follows:
For the Years Ending
December 31,
|
Amount
|
|||
2020 |
$
|
553,189
|
||
2021 |
571,470
|
|||
2022 |
588,918
|
|||
2023 |
606,864
|
|||
2024 |
624,172
|
|||
Thereafter
|
747,656
|
|||
$
|
3,692,269
|
The Company records rent expense on a straight-line basis over the term of the lease. Rent expense charged to operations was $544,214 during the year ended December 31, 2019 and was $77,170 and
$480,577 during the period from November 6, 2018 through December 31, 2018 and the period from January 1, 2018 through November 5, 2018, respectively, which is included in general and administrative expenses in the accompanying Statements of
Operations.
Sublease Agreement
On April 18, 2019, the Company entered into a sublease agreement with Nezu Asia Capital Management, LLC (“the Tenant”), whereby the Tenant agreed to sublease approximately 999 square feet of space
currently rented by the Company in New York, NY, for an initial term of 8 years, commencing on May 15, 2019. The term of the sublease expires on October 31, 2026 with no option to extend the sublease term. Rent payments provided by the Tenant under
the sublease agreement began on September 1, 2019. Annual rent payable to the Company pursuant to the sublease is $78,422 for the first year and the sublease agreement stipulates an annual rent increase of 2.25%. The Tenant also is responsible for
paying to the Company all tenant energy costs, annual operating costs, and annual tax costs attributable to the subleased space during the term of the sublease. The Company received sublease payments of $32,676 during the year ended December 31,
2019.
In connection with the sublease, the Company recognized a loss and a recorded lease liability of $103,350 during the year ended December 31, 2019, representing the discounted cash flows from future
rental payments in excess of the future sublease payments to be received. The loss is included in general and administrative expense on the accompanying Statements of Operations.
NOTE 12 STOCKHOLDERS’ DEFICIENCY AND MEMBERS’ EQUITY
Stockholders’ Deficiency - Predecessor
The number of shares of capital stock that were authorized to be issued by the Predecessor was 171,781,743, consisting of 50,000,000 shares of common stock and 121,781,743 shares of preferred
stock, of which 160,000 shares were designated as Series A Preferred stock, 54,000 shares were designated as Series B Preferred Stock, 41,567,743 shares were designated as Series C Preferred Stock and 80,000,000 shares were designated as Series D
Preferred Stock. The Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock are together the “Preferred Stock.”
During 2018, all shares of Predecessor Series A, Series B and Series C convertible preferred stock were exchanged for 16,771,866 shares of Predecessor common stock. The exchange of Series A, Series
B and Series C convertible preferred stock for common stock was not pursuant to the original terms of the convertible preferred stock; accordingly, the exchange of convertible preferred stock for common was recorded as an extinguishment of the
preferred stock, and the resulting gain on extinguishment was recorded as a credit to accumulated deficit and an increase to net income available to common stockholders.
In connection with the Business Combination (see Note 4 – Business Combination), Predecessor common stockholders and holders of Series D preferred stock received Successor Class C membership units
(see Members’ Equity below) and all outstanding shares of Predecessor common stock and Series D preferred stock were canceled.
14
BROOKLYN IMMUNOTHERAPEUTICS, LLC
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2019 AND
THE PERIODS FROM NOVEMBER 6, 2018 THROUGH DECEMBER 31, 2018 (SUCCESSOR PERIOD)
AND FROM JANUARY 1, 2018 THROUGH NOVEMBER 5, 2018 (PREDECESSOR PERIOD)
Stock Options
The following represents activity related to the Predecessor’s stock options during the period from the January 1, 2018 through November 5, 2018:
Number of
Options
|
Weighted
Average
Exercise
Price
|
Weighted
Average
Remaining
Life in Years
|
Aggregate
Intrinsic
Value
|
|||||||||||||
Outstanding, January 1, 2018
|
1,165
|
$
|
208
|
1.5
|
$
|
-
|
||||||||||
Granted
|
-
|
-
|
-
|
-
|
||||||||||||
Exercised
|
||||||||||||||||
Forfeited
|
(80
|
)
|
$
|
300
|
-
|
-
|
||||||||||
Outstanding, November 5, 2018
|
1,085
|
$
|
201
|
0.7
|
$
|
-
|
||||||||||
Exercisable, November 5, 2018
|
1,085
|
$
|
201
|
0.7
|
$
|
-
|
The following table presents information related to stock options at November 5, 2018:
Options Outstanding
|
Options Exercisable
|
|||||||||||||
Exercise Price
|
Outstanding Number
of Options
|
Weighted Average
Remaining Life In Years
|
Exercisable Number
of Options
|
|||||||||||
$
|
200
|
1,075
|
0.7
|
1,075
|
||||||||||
$
|
300
|
10
|
0.2
|
10
|
||||||||||
1,085
|
0.7
|
1,085
|
In connection with the Business Combination (see Note 4 – Business Combination), all outstanding Predecessor stock options were canceled.
Members’ Equity
Pursuant to the BITX Operating Agreement, the Company is authorized to issue 100,000 non-voting membership units, consisting of 65,000 Class A Units, 15,000 Class B Units, 10,000 Class C Units and
10,000 Common Units. Any distributions are made to the members in the following order and priority: first, on a pro rata basis, to the holders of Class A Units, in proportion to the number of Class A Units held by each, until the Company has made
aggregate distributions of $100 million; second, 75% on a pro rata basis to holders of Class A Units and Common Units, 15% on a pro rata basis to the holders of Class B Units and 10% on a pro rata basis to holders of Class C Units, until the
Company has made aggregate distributions equal to $500 million; thereafter, 65% on a pro rata basis to holders of Class A Units and Common Units, 20% on a pro rata basis to the holders of Class B Units and 15% on a pro rata basis to holders of
Class C Units.
Through December 31, 2018, the Company issued 65,000 Class A Units for in exchange for capital commitments of $22,447,005 and services valued at $5,000. During 2018, the Company made capital calls
in the aggregate amount of $9,953,930. During 2018, the Company received cash of $7,587,584 and exchanged notes payable and interest the amount of $1,516,346 during 2018 in satisfaction of capital calls (see Note 10 – Loans Payable and Loans
Payable to Relate Parties). The remaining $850,000 was recorded as subscriptions receivable as of December 31, 2018 and was received through March 31, 2019. Further, the Company received $638,575 cash representing payments in excess of capital
calls during the year ended December 31, 2018, which is recorded in other current liabilities on the accompanying balance sheet (see Note 9 – Investor Deposits).
During the year ended December 31, 2019, the Company made capital calls in the aggregate amount of $8,218,762 in exchange for Class A Units. The Company received cash of $7,808,250 and applied
investor deposits of $410,512 in satisfaction of capital calls made during 2019. Further, the Company received cash of $437,500 representing payments in excess of capital calls during the years ended December 31, 2019 and 2018, respectively, which
is recorded in other current liabilities on the accompanying balance sheet (see Note 9 – Investor Deposits).
15
BROOKLYN IMMUNOTHERAPEUTICS, LLC
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2019 AND
THE PERIODS FROM NOVEMBER 6, 2018 THROUGH DECEMBER 31, 2018 (SUCCESSOR PERIOD)
AND FROM JANUARY 1, 2018 THROUGH NOVEMBER 5, 2018 (PREDECESSOR PERIOD)
On November 6, 2018, the Company issued 15,000 Class B Units with an aggregate grant date value of $1,400,000 and issued 10,000 Class C Units with an aggregate grant date value of $1,000,000 to
former stockholders and debt holders of IRX, in connection with the Business Combination (see Note 4 – Business Combination). Management, with the assistance of an independent valuation firm, utilized the market approach and an option pricing model
(“OPM”) to allocate the transaction equity value to the respective classes of membership units. The inputs to the OPM included (a) the $22 million equity value; (b) term of 3.5 years; (c) volatility of 100%; (d) risk-free rate of 3.01%; and (e)
expected dividend rate of 0.0%.
During the period from November 6, 2018 through December 31, 2018, the Company granted 4,125 of restricted common units to certain employees valued at $88.75 per unit, or an aggregate of $366,094.
On September 23, 2019, the company granted 125 restricted common units valued at $88.75 per unit, or $11,094, to a single employee. The units vest 25% on the first anniversary of the date of grant, and the remainder vest monthly over the following
three years. The Company recorded stock-based compensation expense of $91,689 during the year ended December 31, 2019 and recognized $20,248 during the period from November 6 through December 31, 2018, related to the amortization of the restricted
common units, which is included in general and administrative expenses on the accompanying statements of operations.
NOTE 13 INCOME TAX
The Successor is a limited liability company treated as a partnership for federal and state income tax purposes, and the taxable income or loss is passed through to its members. The Successor is
subject to the Unincorporated Business Tax (“UBT”) on taxable income attributable to New York City. As of December 31, 2019, the Company has an operating loss carryforward of approximately $10,941,526 available to offset future taxable income,
which does not expire.
The Successor files its Federal, New York State, and New York City returns. The Federal, New York State, and New York City returns for the years ended December 31, 2019 and 2018 remain open to
examination. The Successor is not currently undergoing any tax audit and has not received notice of an audit. The Successor tax benefits for the year and December 31, 2019 and for the period from November 6, 2018 through December 31, 2018 result
from increases in the gross deferred tax assets and are offset by a corresponding tax expense due to an increase in the valuation allowance associated with those same deferred tax assets, resulting in an effective tax rate of 0%.
The Predecessor filed its income tax returns in the U.S. Federal jurisdiction, the state of New York and New York City. Federal, state and city income tax returns, for the years ended December 31,
2016 through December 31, 2018 remain open to examination by the IRS and state jurisdictions. The Predecessor is not currently undergoing any audit and has not received notice of audit or any notifications from the IRS for any of the open tax
years.
The Predecessor tax benefits during each period, which resulted from increases in the gross deferred tax assets as well as tax credits related to qualified research and development expenses
incurred during the period, were offset by a corresponding tax expense due to an increase in the valuation allowance associated with those same deferred tax assets, resulting in an effective tax rate of 0%.
The income tax benefit consists of the following:
Successor
|
Predecessor
|
|||||||||||
For the Year
Ended December 31,
2019
|
For the period
from November 6,
2018 through
December 31,
2018
|
For the period
from January 1,
2018 through
November 5, 2018
|
||||||||||
Federal:
|
||||||||||||
Current
|
$
|
-
|
$
|
-
|
$
|
-
|
||||||
Deferred
|
-
|
-
|
8,266,417
|
|||||||||
State and local:
|
||||||||||||
Current
|
-
|
|||||||||||
Deferred
|
357,482
|
80,179
|
5,438,948
|
|||||||||
357,482
|
80,179
|
13,705,365
|
||||||||||
Change in valuation allowance
|
(357,482
|
)
|
(80,179
|
)
|
(13,705,365
|
)
|
||||||
Income tax benefit (provision)
|
$
|
-
|
$
|
-
|
$
|
-
|
16
BROOKLYN IMMUNOTHERAPEUTICS, LLC
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2019 AND
THE PERIODS FROM NOVEMBER 6, 2018 THROUGH DECEMBER 31, 2018 (SUCCESSOR PERIOD)
AND FROM JANUARY 1, 2018 THROUGH NOVEMBER 5, 2018 (PREDECESSOR PERIOD)
Deferred tax assets and liabilities consist of the effects of temporary differences as shown in the table below. Deferred tax assets have been fully reserved by a valuation allowance since it is
more likely than not that such tax benefits will not be realized.
December 31,
|
||||||||
2019
|
2018
|
|||||||
Deferred tax assets:
|
||||||||
Net operating loss carryforward
|
$
|
424,800
|
$
|
80,179
|
||||
Less: valuation allowance
|
(424,800
|
)
|
(80,179
|
)
|
||||
Total
|
$
|
-
|
$
|
-
|
NOTE 14 SUBSEQUENT EVENTS
Capital Call
Subsequent to December 31, 2019, the Company made capital calls in the aggregate amount of $3,858,750. The Company received cash of $3,858,750 in satisfaction of this capital call through the dates
which the financial statements were available to be issued.
CARES Act
On March 27, 2020, President Trump signed into law the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”). The CARES Act, among other things, includes provisions relating to refundable
payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax
depreciation methods for qualified improvement property. Under ASC 740, the effects of new legislation are recognized upon enactment. Accordingly, the effects of the CARES Act will be effective in the quarter, or in our case, the year that includes
the date that the president signs the bill. We are currently evaluating how provisions in the CARES Act will impact our financial statements in 2020.
Exhibit 99.3
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS
The following unaudited pro forma condensed combined financial statements give effect to the merger of BIT Merger Sub, Inc. (“Merger Sub”), a wholly owned subsidiary of NTN Buzztime, Inc. (“NTN”), with and into
Brooklyn ImmunoTherapeutics LLC (“Brooklyn LLC”), in a transaction accounted for as a reverse merger (the “Merger”). In connection with the Merger, NTN changed its name from NTN Buzztime, Inc. to Brooklyn ImmunoTherapeutics, Inc. (the “Company”).
The Merger closed on March 25, 2021 and the following information gives effect to a 1-for-2 reverse stock split (“Reverse Stock Split”) of common stock, par value $0.005 per share (“Common Stock”), effective on
that date. All pro forma numbers and per share amounts of Common Stock have been retroactively restated to reflect the Reverse Stock Split. On March 26, 2021, the Company sold (the “Disposition”) its rights, title and interest in and to the
assets relating to the business it operated prior to the Merger, which was operated under the name NTN Buzztime, Inc. to eGames.com Holdings LLC (“eGames.com”) in accordance with the terms of an asset purchase agreement dated September 18, 2020,
as amended, between NTN and eGames.com (the “Asset Purchase Agreement”).
The Merger is accounted for as a reverse acquisition under United States generally accepted accounting principles (“U.S. GAAP”). Brooklyn LLC was determined to be the accounting acquirer based on the following
factors (i) Brooklyn LLC members and Maxim Group LLC, Brooklyn LLC’s financial adviser (the “Financial Adviser”), received shares of Common Stock representing 96.37% of the Common Stock outstanding on a fully diluted basis immediately following
the effective time of the Merger, (ii) Brooklyn LLC had the right to appoint all of the Company’s directors effective immediately following the Merger and (iii) immediately following the Merger, Brooklyn LLC’s management were appointed to hold
all key positions in the management of the Company.
The following unaudited pro forma condensed combined financial statements give effect to (i) the Merger, (ii) Brooklyn LLC’s rights offering related to the Merger (the “Brooklyn LLC Rights Offering”) and (iii) the
Disposition (collectively, the “Pro Forma Events”).
The unaudited pro forma condensed combined financial statements are based on NTN’s historical consolidated financial statements and Brooklyn LLC’s historical financial statements as adjusted to give effect to the
Pro Forma Events. The unaudited pro forma condensed combined balance sheet as of December 31, 2020 gives effect to the Pro Forma Events as if those transactions took place on December 31, 2020. The unaudited pro forma condensed combined statement
of operations for the year ended December 31, 2020 gives effect to the Pro Forma Events as if those transactions took place on January 1, 2020. The historical financial statements of NTN and Brooklyn LLC have been adjusted to give pro forma
effect to transactions that are (i) directly attributable to the Pro Forma Events, (ii) factually supportable, and (iii) with respect to the statement of operations, expected to have a continuing impact on the combined results of operations of
the Company.
The unaudited pro forma condensed combined financial statements are based on the assumptions and adjustments described in the accompanying notes. The unaudited pro forma condensed combined financial statements and
pro forma adjustments relating to the Merger and the Disposition have been prepared based on preliminary estimates of fair value of assets acquired and liabilities assumed and disposed as of the date of the completion of each transaction.
Differences between these preliminary estimates and the final fair value of assets and liabilities acquired and disposed may occur and these differences could have a material impact on the accompanying unaudited pro forma condensed combined
financial statements and the Company’s future results of operations and financial position.
The unaudited pro forma condensed combined financial statements do not give effect to the potential impact of current financial conditions, regulatory matters, operating efficiencies or other savings or expenses
that may be associated with the integration of the two companies. The unaudited pro forma condensed combined financial statements have been prepared for illustrative purposes only and are not necessarily indicative of the financial position or
results of operations in future periods or the results that actually would have been realized had Brooklyn LLC and NTN been a combined company during the specified period.
1
UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET AS OF DECEMBER 31, 2020
Historical
|
||||||||||||||||||||||||||||||
Brooklyn Immunotherapeutics, LLC
|
NTN Buzztime, Inc.
|
Pro Forma
Adjustments –
Merger
|
Notes to Pro Forma Adjustments
|
Pro Forma
Adjustments –
Merger (Combined)
|
Pro Forma
Adjustments –
Sale of Assets
|
Notes to Pro Forma Adjustments
|
Pro Forma
Combined
|
|||||||||||||||||||||||
Assets
|
||||||||||||||||||||||||||||||
Current Assets:
|
||||||||||||||||||||||||||||||
Cash and cash equivalents
|
$
|
1,630,455
|
$
|
777,383
|
$
|
10,500,000
|
A |
|
$
|
12,907,838
|
$
|
(213,566
|
)
|
E |
|
$
|
12,694,272
|
|||||||||||||
Accounts receivable, net
|
-
|
115,680
|
-
|
115,680
|
836
|
E |
|
116,516
|
||||||||||||||||||||||
Site equipment to be installed
|
-
|
654,602
|
(654,602
|
)
|
C |
|
-
|
-
|
-
|
|||||||||||||||||||||
Prepaid expenses and other current assets
|
102,322
|
176,830
|
-
|
279,152
|
(75,435
|
)
|
E |
|
203,717
|
|||||||||||||||||||||
Total Current Assets
|
1,732,777
|
1,724,495
|
9,845,398
|
13,302,670
|
(288,165
|
)
|
13,014,505
|
|||||||||||||||||||||||
Long Term Assets:
|
||||||||||||||||||||||||||||||
Property and equipment, net
|
594,106
|
501,804
|
654,602
|
C |
|
1,750,512
|
(1,156,405
|
)
|
E |
|
594,107
|
|||||||||||||||||||
Customers
|
-
|
-
|
548,000
|
C |
|
548,000
|
(548,000
|
)
|
E |
|
-
|
|||||||||||||||||||
Trade name
|
-
|
-
|
299,000
|
C |
|
299,000
|
(299,000
|
)
|
E |
|
-
|
|||||||||||||||||||
Right of use assets - operating leases
|
2,092,878
|
35,616
|
-
|
2,128,494
|
(35,616
|
)
|
E |
|
2,092,878
|
|||||||||||||||||||||
Software development costs, net of accumulated amortization
|
-
|
1,360,915
|
(432,915
|
)
|
C |
|
928,000
|
(928,000
|
)
|
E |
|
-
|
||||||||||||||||||
Goodwill
|
2,043,747
|
-
|
6,868,944
|
C |
|
8,912,691
|
(6,868,944
|
)
|
E |
|
2,043,747
|
|||||||||||||||||||
In process research and development
|
6,860,000
|
-
|
-
|
6,860,000
|
-
|
6,860,000
|
||||||||||||||||||||||||
Security deposits and other assets
|
453,252
|
-
|
-
|
453,252
|
-
|
453,252
|
||||||||||||||||||||||||
Other assets
|
-
|
122,291
|
-
|
122,291
|
(88,028
|
)
|
E |
|
34,263
|
|||||||||||||||||||||
Total Assets
|
$
|
13,776,760
|
$
|
3,745,121
|
$
|
17,783,029
|
$
|
35,304,910
|
$
|
(10,212,158
|
)
|
$
|
25,092,752
|
See accompanying notes to Unaudited Pro Forma Condensed Combined Financial Statements.
2
UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET AS OF DECEMBER 31, 2020 (CONTINUED)
Historical
|
||||||||||||||||||||||||||||||
Brooklyn Immunotherapeutics, LLC
|
NTN Buzztime, Inc.
|
Pro Forma
Adjustments –
Merger
|
Notes to Pro Forma Adjustments
|
Pro Forma
Adjustments –
Merger (Combined)
|
Pro Forma
Adjustments –
Sale of Assets
|
Notes to Pro Forma Adjustments
|
Pro Forma
Combined
|
|||||||||||||||||||||||
Liabilities and Stockholders’ Equity
|
||||||||||||||||||||||||||||||
Current Liabilities:
|
||||||||||||||||||||||||||||||
Accounts payable and accrued expenses
|
$
|
2,326,243
|
$
|
571,763
|
$
|
1,048,915
|
B |
|
$
|
3,946,921
|
$
|
165,314
|
E |
|
$
|
4,112,235
|
||||||||||||||
Loans payable
|
410,000
|
-
|
-
|
410,000
|
-
|
410,000
|
||||||||||||||||||||||||
PPP loan, current
|
115,972
|
-
|
-
|
115,972
|
-
|
115,972
|
||||||||||||||||||||||||
Taxes payable
|
-
|
15,366
|
-
|
15,366
|
(23,803
|
)
|
E |
|
(8,437
|
)
|
||||||||||||||||||||
Current portion of long-term debt, net
|
-
|
1,500,000
|
-
|
1,500,000
|
(1,500,000
|
)
|
E |
|
-
|
|||||||||||||||||||||
Current portion of lease liability
|
273,217
|
35,616
|
-
|
308,833
|
(35,616
|
)
|
E |
|
273,217
|
|||||||||||||||||||||
Current portion of obligations under finance leases
|
-
|
21,800
|
-
|
21,800
|
(21,800
|
)
|
E |
|
-
|
|||||||||||||||||||||
Current portion of deferred revenue
|
-
|
76,123
|
-
|
76,123
|
(76,123
|
)
|
E |
|
-
|
|||||||||||||||||||||
Other current liabilities
|
-
|
139,752
|
-
|
139,752
|
(121,692
|
)
|
E |
|
18,060
|
|||||||||||||||||||||
Total Current Liabilities
|
3,125,432
|
2,360,420
|
1,048,915
|
6,534,767
|
(1,613,720
|
)
|
4,921,047
|
|||||||||||||||||||||||
Long Term Liabilities:
|
||||||||||||||||||||||||||||||
Contingent consideration
|
20,110,000
|
-
|
-
|
20,110,000
|
-
|
20,110,000
|
||||||||||||||||||||||||
Lease liability, non-current
|
1,905,395
|
-
|
-
|
1,905,395
|
-
|
1,905,395
|
||||||||||||||||||||||||
PPP loan, non-current
|
193,933
|
531,979
|
-
|
725,912
|
(531,979
|
)
|
E |
|
193,933
|
|||||||||||||||||||||
Long-term obligations under finance leases
|
-
|
85
|
-
|
85
|
(85
|
)
|
E |
|
-
|
|||||||||||||||||||||
Long-term deferred revenue
|
-
|
1,803
|
-
|
1,803
|
(1,803
|
)
|
E |
|
-
|
|||||||||||||||||||||
Other liabilities
|
22,863
|
-
|
-
|
22,863
|
-
|
22,863
|
||||||||||||||||||||||||
Total Liabilities
|
25,357,623
|
2,894,287
|
1,048,915
|
29,300,825
|
(2,147,587
|
)
|
27,153,238
|
|||||||||||||||||||||||
Commitments and contingencies
|
||||||||||||||||||||||||||||||
Stockholders’ Equity:
|
||||||||||||||||||||||||||||||
Class A membership units
|
23,202,005
|
-
|
10,500,000
|
A |
|
-
|
-
|
-
|
||||||||||||||||||||||
(33,702,005
|
)
|
D |
|
|||||||||||||||||||||||||||
Class B membership units
|
1,400,000
|
-
|
(1,400,000
|
)
|
D |
|
-
|
-
|
-
|
|||||||||||||||||||||
Class C membership units
|
1,000,000
|
-
|
(1,000,000
|
)
|
D |
|
-
|
-
|
-
|
|||||||||||||||||||||
Common units
|
197,873
|
-
|
(197,873
|
)
|
D |
|
-
|
-
|
-
|
|||||||||||||||||||||
Series A preferred stock
|
-
|
781
|
-
|
D |
|
781
|
-
|
781
|
||||||||||||||||||||||
Common stock, $0.005 par value
|
-
|
14,832
|
5,339
|
B |
|
207,529
|
-
|
207,529
|
||||||||||||||||||||||
187,358
|
D |
|
||||||||||||||||||||||||||||
Treasury stock
|
-
|
(456,450
|
)
|
456,450
|
D |
|
-
|
-
|
-
|
|||||||||||||||||||||
Additional paid-in capital
|
-
|
136,933,763
|
5,761,207
|
B |
|
49,991,977
|
-
|
49,991,977
|
||||||||||||||||||||||
(92,702,993
|
)
|
D |
|
|||||||||||||||||||||||||||
Accumulated deficit
|
(37,380,741
|
)
|
(135,887,313
|
)
|
(6,815,461
|
)
|
B |
|
(44,196,202
|
)
|
(8,064,571
|
)
|
E |
|
(52,260,773
|
)
|
||||||||||||||
135,887,313
|
D |
|
||||||||||||||||||||||||||||
Accumulated other comprehensive income
|
-
|
245,221
|
(245,221
|
)
|
D |
|
-
|
-
|
-
|
|||||||||||||||||||||
Total Stockholders’ Equity
|
(11,580,863
|
)
|
850,834
|
16,734,114
|
6,004,085
|
(8,064,571
|
)
|
(2,060,486
|
)
|
|||||||||||||||||||||
Total Liabilities and Stockholders’ Equity
|
$
|
13,776,760
|
$
|
3,745,121
|
$
|
17,783,029
|
$
|
35,304,910
|
$
|
(10,212,158
|
)
|
$
|
25,092,752
|
See accompanying notes to Unaudited Pro Forma Condensed Combined Financial Statements.
3
UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS FOR THE YEAR ENDED DECEMBER 31, 2020
Historical
|
||||||||||||||||||||||||||||
Brooklyn Immunotherapeutics, LLC
|
NTN Buzztime, Inc.
|
Pro Forma
Adjustments –
Merger
|
Notes to Pro Forma Adjustments
|
Pro Forma
Adjustments –
Merger (Combined)
|
Pro Forma
Adjustments –
Sale of Assets
|
Notes to Pro Forma Adjustments
|
Pro Forma
Combined
|
|||||||||||||||||||||
Revenue:
|
||||||||||||||||||||||||||||
Subscription revenue
|
$
|
-
|
$
|
4,881,615
|
$
|
-
|
$
|
4,881,615
|
$
|
(4,881,615
|
)
|
E |
$
|
-
|
||||||||||||||
Hardware revenue
|
-
|
426,046
|
-
|
426,046
|
(426,046
|
)
|
E |
-
|
||||||||||||||||||||
Other revenue
|
-
|
492,723
|
-
|
492,723
|
(492,723
|
)
|
E |
-
|
||||||||||||||||||||
Total revenue
|
-
|
5,800,384
|
-
|
5,800,384
|
(5,800,384
|
)
|
-
|
|||||||||||||||||||||
Operating Expenses:
|
||||||||||||||||||||||||||||
General and administrative
|
3,296,851
|
-
|
-
|
3,296,851
|
-
|
3,296,851
|
||||||||||||||||||||||
Selling, general and administrative
|
-
|
8,091,385
|
-
|
8,091,385
|
(8,091,385
|
)
|
E |
-
|
||||||||||||||||||||
Research and development
|
3,951,253
|
-
|
-
|
3,951,253
|
-
|
3,951,253
|
||||||||||||||||||||||
Direct operating costs
|
-
|
2,907,058
|
-
|
2,907,058
|
(2,907,058
|
)
|
E |
-
|
||||||||||||||||||||
Impairment of capitalized software
|
-
|
247,733
|
-
|
247,733
|
(247,733
|
)
|
E |
-
|
||||||||||||||||||||
Impairment of goodwill
|
-
|
661,620
|
-
|
661,620
|
(661,620
|
)
|
E |
-
|
||||||||||||||||||||
Depreciation and amortization (excluding depreciation and amortization included in direct operating costs)
|
-
|
201,128
|
-
|
201,128
|
(201,128
|
)
|
E |
-
|
||||||||||||||||||||
Change in fair value of contingent consideration
|
19,240,000
|
-
|
-
|
19,240,000
|
-
|
19,240,000
|
||||||||||||||||||||||
Total operating expenses
|
26,488,104
|
12,108,924
|
-
|
38,597,028
|
(12,108,924
|
)
|
26,488,104
|
|||||||||||||||||||||
Loss from operations
|
(26,488,104
|
)
|
(6,308,540
|
)
|
-
|
(32,796,644
|
)
|
6,308,540
|
(26,488,104
|
)
|
||||||||||||||||||
Other Expenses:
|
||||||||||||||||||||||||||||
Interest expense, net
|
(42,957
|
)
|
(138,528
|
)
|
-
|
(181,485
|
)
|
138,528
|
E |
(42,957
|
)
|
|||||||||||||||||
Other income, net
|
-
|
2,025,178
|
-
|
2,025,178
|
(2,025,178
|
)
|
E |
-
|
||||||||||||||||||||
Total other (expense) income, net
|
(42,957
|
)
|
1,886,650
|
-
|
1,843,693
|
(1,886,650
|
)
|
(42,957
|
)
|
|||||||||||||||||||
Loss before income taxes
|
(26,531,061
|
)
|
(4,421,890
|
)
|
-
|
(30,952,951
|
)
|
4,421,890
|
(26,531,061
|
)
|
||||||||||||||||||
Benefit for income taxes
|
-
|
6,407
|
-
|
6,407
|
(6,407
|
)
|
E |
-
|
||||||||||||||||||||
Loss from continuing operations
|
(26,531,061
|
)
|
(4,415,483
|
)
|
-
|
(30,946,544
|
)
|
4,415,483
|
(26,531,061
|
)
|
||||||||||||||||||
Series A preferred stock dividend
|
-
|
(15,612
|
)
|
-
|
(15,612
|
)
|
-
|
(15,612
|
)
|
|||||||||||||||||||
Net loss attributable to common stockholders
|
$
|
(26,531,061
|
)
|
$
|
(4,431,095
|
)
|
$
|
-
|
$
|
(30,962,156
|
)
|
$
|
4,415,483
|
$
|
(26,546,673
|
)
|
||||||||||||
Net loss per common share - basic and diluted
|
$
|
(1.51
|
)
|
$
|
(0.75
|
)
|
$
|
(0.64
|
)
|
|||||||||||||||||||
Weighted average shares outstanding - basic and diluted
|
2,928,160
|
F |
|
41,463,840
|
41,463,840
|
|||||||||||||||||||||||
Comprehensive loss:
|
||||||||||||||||||||||||||||
Foreign currency translation adjustment
|
-
|
(22,675
|
)
|
-
|
(22,675
|
)
|
22,675
|
E |
-
|
|||||||||||||||||||
Total comprehensive loss
|
$
|
(26,531,061
|
)
|
$
|
(4,438,158
|
)
|
$
|
-
|
$
|
(30,969,219
|
)
|
$
|
4,438,158
|
$
|
(26,531,061
|
)
|
See accompanying notes to Unaudited Pro Forma Condensed Combined Financial Statements.
4
NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS
1. Description of the Transactions and Basis of Presentation
The unaudited pro forma condensed combined financial statements were prepared in accordance with U.S. GAAP and pursuant to the rules and regulations of SEC Regulation S-X and presents the pro
forma financial position and results of operations of the combined company based upon the historical data of Brooklyn LLC and NTN.
Merger
On March 25, 2021, the Merger closed. In connection with, and immediately prior to the completion of, the Merger, NTN effected the Reverse Stock Split, in which shares of Common Stock was split
at a ratio of 1-for-2. Immediately after completion of the Merger, NTN changed its name to Brooklyn ImmunoTherapeutics, Inc.
Under the terms of the agreement and plan of merger and reorganization dated August 12, 2020 among the Company, the Merger Sub and Brooklyn LLC with respect to the Merger
(the “Merger Agreement”), at the effective time of the Merger the members of Brooklyn LLC exchanged all of their equity interests in Brooklyn LLC for an aggregate of 39,999,760 shares of Common Stock, of which 1,067,879 shares were issued as
compensation to the Financial Adviser for its services to Brooklyn LLC in connection with the Merger. The terms of the exchange of Brooklyn LLC’s equity interests for Common Stock were determined through an arm’s-length negotiation between
Brooklyn LLC and NTN in connection with the negotiation of the Merger Agreement.
Immediately after the Merger and the Reverse Stock Split, there were outstanding:
• |
41,506,031 shares of Common Stock, of which 96.37% were held by the former members of Brooklyn LLC and the Financial Adviser, as the result of its compensation in connection with the Merger, and 3.63% were held by holders of Common
Stock as of immediately prior to the Merger;
|
• |
156,112 shares of NTN’s Series A 10% convertible preferred stock, which were convertible into approximately 42,027 shares of Common Stock and which continued to be owned by their holders as of immediately before the Merger; and
|
• |
stock options to purchase an aggregate of 13,020 shares of Common Stock.
|
The Merger has been accounted for as a business combination using the acquisition method of accounting under the provisions of Financial Accounting Standards Board Accounting Standards
Codification Topic 805, Business Combinations (“ASC 805”). The Merger was accounted for as a reverse acquisition with Brooklyn LLC being deemed the acquiring company for accounting purposes. Under ASC 805, Brooklyn LLC, as the accounting
acquirer, will record the NTN assets acquired and liabilities assumed in the Merger at their fair values as of the acquisition date.
5
Brooklyn LLC Rights Offering
As a condition to the closing of the Merger under the Merger Agreement, Brooklyn LLC was required to have at least $10,000,000 in cash and cash equivalents at the effective time of the Merger.
In furtherance of, and prior to, the Merger, certain members of Brooklyn LLC entered into agreements with Brooklyn LLC pursuant to which those members purchased, in the Brooklyn LLC Rights Offering, units of Brooklyn LLC for an aggregate purchase
price of $10,500,000.
Disposition
In the Disposition completed on March 26, 2021, the Company sold its rights, title and interest in and to the assets relating to the business operated by NTN prior to the Merger to eGames.com in
exchange for a payment of a purchase price of $2,000,000 and assumption of specified liabilities relating to the NTN business. The Disposition was completed in accordance with the terms of the Asset Purchase Agreement.
Following the Company entering into the Asset Purchase Agreement, it borrowed a total of $1,700,000 by issuing to Fertilemind Management, LLC, an affiliate of eGames.com, three unsecured
promissory notes: a note in the principal amount of $1,000,000 issued as of September 18, 2020; a note in the principal amount of $500,000 issued as of December 1, 2020; and a note in the principal amount of $200,000 issued on January 12, 2021.
All of these notes (including interest accrued to the amount of $67,945) were cancelled as of the closing of the Disposition in partial satisfaction of the purchase price of $2,000,000 payable by eGames.com under the Asset Purchase Agreement. The
remainder of the purchase price was settled in cash to the amount of $232,055 of which $100,000 have been placed in escrow as per the terms of the Asset Purchase Agreement.
Basis of Presentation
The historical financial statements of NTN and Brooklyn LLC have been adjusted to give pro forma effect to transactions that are (i) directly attributable to the Pro Forma Events, (ii) factually
supportable, and (iii) with respect to the statement of operations, expected to have a continuing impact on the combined results. The adjustments in the unaudited pro forma condensed combined financial statements have been identified and
presented to provide relevant information necessary for an accurate understanding of the combined entity upon consummation of the Pro Forma Events.
The pro forma condensed combined financial statements do not give effect to the potential impact of current financial conditions, regulatory matters, operating efficiencies or other savings or
expenses that may be associated with the integration of the two companies. The unaudited pro forma condensed combined financial statements have been prepared for illustrative purposes only and is not necessarily indicative of the financial
position or results of operations in future periods or the results that actually would have been realized had the Pro Forma Events occurred on the dates indicated. They also may not be useful in predicting the future financial condition and
results of operations of the combined company. The actual financial position and results of operations may differ significantly from the pro forma amounts reflected herein due to a variety of factors.
Because Brooklyn LLC is treated as the accounting acquirer, Brooklyn LLC’s assets and liabilities are recorded at their pre-combination carrying amounts, and the historical operations that are
reflected in the financial statements will be those of Brooklyn LLC. NTN’s assets and liabilities are measured and recognized at their fair values as of the Merger date, and consolidated with the assets, liabilities and results of operations of
Brooklyn LLC after the consummation of the Merger. The Disposition reflects the removal of the assets and liabilities and results of operations and non-recurring costs directly related to the NTN business.
The Reverse Stock Split effective March 25, 2021 has been reflected in the unaudited pro forma condensed combined financial statements.
6
2. Preliminary Purchase Price Allocation for Acquisition
The purchase price, which represents the consideration transferred in the Merger to NTN’s stockholders, is calculated based on the fair value of the Common Stock of the combined company that
NTN’s stockholders owned as of the closing date of the Merger because that represents a more reliable measure of the fair value of consideration transferred in the Merger. Accordingly, the accompanying unaudited pro forma condensed combined
financial statements reflects a purchase price of $8,133,863, which was calculated as follows
Number of shares of the Common Stock owned by NTN stockholders (i)
|
1,506,271
|
|||
Multiplied by the fair value per share of Common Stock (ii)
|
5.40
|
|||
Total purchase price
|
$
|
8,133,863
|
(i)
|
The purchase price was determined based on the number of shares of Common Stock of the combined company that NTN’s stockholders owned immediately prior to the Merger.
|
(ii)
|
The fair value per share is based on the closing price of $5.40 (post Reverse Stock Split) per share of the Common Stock as reported on the NYSE American on March 25, 2021, the date of the Merger.
|
Under the acquisition method of accounting, the total purchase price is allocated to the acquired tangible and intangible assets and assumed liabilities of NTN based on their estimated fair
values as of the Merger closing date. Because the consideration paid by Brooklyn LLC in the Merger is more than the estimated fair values of NTN’s net assets acquired, goodwill equal to the difference has been reflected in the unaudited pro forma
condensed combined balance sheet. The goodwill of $6,868,944 determined for the purpose of this unaudited pro forma condensed combined financial statements has been calculated using preliminary estimate of the fair values of the net assets of NTN
as of December 31, 2020. The final determination of the amount of goodwill will be based on the final determination of the fair values of the net assets of NTN acquired on the closing date of the Merger, which may be materially different from the
estimated amount as of December 31, 2020.
The preliminary allocation of the estimated purchase price to the tangible and intangible assets acquired and liabilities assumed from NTN, based on their estimated fair values as of December 31, 2020, is as
follows
Historical Balance Sheet of NTN at December 31, 2020
|
Pro Forma Fair Value Adjustment to NTN Assets
|
Preliminary Purchase Price
Allocation Pro Forma Adjustment
|
||||||||||
Cash and cash equivalents
|
$
|
777,383
|
$
|
-
|
$
|
777,383
|
||||||
Accounts receivable
|
115,680
|
-
|
115,680
|
|||||||||
Prepaid expense and other current assets
|
299,121
|
-
|
299,121
|
|||||||||
Right of use assets - operating leases
|
35,616
|
-
|
35,616
|
|||||||||
Property and equipment, net
|
1,156,406
|
-
|
1,156,406
|
|||||||||
Software development costs
|
1,360,915
|
(432,915
|
)
|
928,000
|
||||||||
Customers
|
-
|
548,000
|
548,000
|
|||||||||
Trade name
|
-
|
299,000
|
299,000
|
|||||||||
Accounts payable, accrued liabilities and other current liabilities
|
(2,894,287
|
)
|
-
|
(2,894,287
|
)
|
|||||||
Net assets acquired, excluding goodwill
|
$
|
850,834
|
$
|
414,085
|
$
|
1,264,919
|
||||||
Total consideration
|
$
|
8,133,863
|
||||||||||
Net assets acquired, excluding goodwill
|
1,264,919
|
|||||||||||
Goodwill
|
$
|
6,868,944
|
7
2. Preliminary Purchase Price Allocation for Acquisition (Continued)
This preliminary purchase price allocation has been used to prepare pro forma adjustments in the combined pro forma balance sheet and statement of operations. Accordingly, the pro forma
adjustments reflected in the unaudited pro forma condensed combined financial statements are preliminary and based on estimates, subject to further revision as additional information becomes available and additional analysis are performed. Using
total consideration for the Merger, management has allocated such consideration to the assets acquired and liabilities assumed of NTN in the Merger based on a valuation analysis and purchase price allocation.
The final purchase price allocation will be determined when management of the combined company has completed the detailed valuations and other studies and necessary calculations. The final
purchase price allocation could differ materially from the preliminary purchase price allocation used to prepare the pro forma adjustments and the unaudited pro forma condensed combined balance sheet.
The final purchase price allocation may result in (a) changes in the identification and allocations to intangible assets such as trade name, acquired technology, and customer relationships as
well as goodwill and (b) other changes to assets and liabilities. In addition, differences between the preliminary and final adjustments will likely occur as a result of the amount of cash used for NTN’s operations and other changes in NTN’s
assets and liabilities between December 31, 2020 and the closing date of the Merger.
3. Disposition of NTN Business to eGames.com
In the Disposition, the Company sold specified NTN assets and liabilities acquired as a result of the reverse acquisition to eGames.com, an unrelated party, for cash consideration of $2,000,000.
Details of the Disposition are as follows:
Proceeds from sale:
|
||||
Cash
|
$
|
132,055
|
||
Escrow
|
100,000
|
|||
Assume advance/loans
|
1,700,000
|
|||
Interest on advance/loans
|
67,945
|
|||
Carrying value of assets sold:
|
||||
Cash and cash equivalents
|
(13,642
|
)
|
||
Accounts receivable
|
(99,164
|
)
|
||
Prepaids and other current assets
|
(75,435
|
)
|
||
Property and equipment, net
|
(1,156,405
|
)
|
||
Software development costs
|
(928,000
|
)
|
||
Customers
|
(548,000
|
)
|
||
Trade name
|
(299,000
|
)
|
||
Right of use assets - operating leases
|
(35,616
|
)
|
||
Goodwill
|
(6,868,944
|
)
|
||
Other assets
|
(88,028
|
)
|
||
Liabilities transferred upon sale:
|
||||
Accounts payable and accrued expenses
|
94,519
|
|||
Obligations under finance leases
|
21,885
|
|||
Lease liability
|
35,616
|
|||
Deferred revenue
|
77,925
|
|||
Other current liabilities
|
121,691
|
|||
Transaction costs
|
(265,000
|
)
|
||
Total loss on sale of assets
|
$
|
(8,025,598
|
)
|
8
4. Pro Forma Adjustments
The unaudited pro forma condensed combined financial statements include pro forma adjustments that are (1) directly attributable to the Pro Forma Events, (2) factually supportable, and (3) with
respect to the unaudited pro forma condensed combined statement of operations, expected to have a continuing impact on the results of operations of the combined company.
The pro forma adjustments are based on estimates and assumptions that are subject to change. The following adjustments have been reflected in the unaudited pro forma condensed combined financial
statements:
A.
|
To reflect gross proceeds of $10,500,000 received by Brooklyn LLC prior to the Merger from the Brooklyn LLC Rights Offering.
|
B.
|
To reflect Brooklyn LLC’s estimate of acquisition-related transaction costs not included in accrued liabilities as of December 31, 2020, as calculated below:
|
Total transaction costs
|
$
|
6,815,461
|
||
Issuance of Common Stock to the Financial Adviser upon consummation of Merger
|
(5,766,546
|
)
|
||
Accrued transaction costs
|
$
|
1,048,915
|
C.
|
To reflect adjusting fair values of the net assets acquired through the Merger, as reflected in Note 2.
|
9
D.
|
To record the (i) elimination of NTN’s historical equity, (ii) the elimination of Brooklyn LLC’s historical members’ equity, (iii) an adjustment for the transaction price, including the fair value of Common Stock retained by NTN’s stockholders, (iv) Series A 10% convertible preferred stock retained by NTN stockholders (v) issuance of Common Stock to the members of Brooklyn LLC in connection with the Merger, and (vi) transaction costs associated with the Merger. |
|
Common stock
|
Series A preferred stock
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||
Membership units |
Shares
|
Amount
|
Shares
|
Amount
|
Treasury stock | Additional paid-in capital |
Accumulated deficit | Accumulated other comprehensive income | Total stockholders’ equity | |||||||||||||||||||||||||||||||
Elimination of NTN’s historical equity carrying value(1)
|
$
|
-
|
(2,962,866
|
)
|
$
|
(14,832
|
)
|
(156,112
|
)
|
$
|
(781
|
)
|
$
|
456,450
|
$
|
(136,933,763
|
)
|
$
|
135,887,313
|
$
|
(245,221
|
)
|
$
|
(850,834
|
)
|
|||||||||||||||
Brooklyn rights offerings membership units
|
10,500,000
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
10,500,000
|
||||||||||||||||||||||||||||||
Elimination of Brooklyn’s historical members’ equity
|
(36,299,878
|
)
|
-
|
-
|
-
|
-
|
-
|
36,299,878
|
-
|
-
|
-
|
|||||||||||||||||||||||||||||
Common Stock to be retained by NTN stockholders
|
-
|
1,506,271
|
7,531
|
-
|
-
|
-
|
8,126,332
|
-
|
-
|
8,133,863
|
||||||||||||||||||||||||||||||
Issuance of Series A preferred stock retained by NTN stockholders
|
-
|
-
|
-
|
156,112
|
781
|
-
|
(781
|
)
|
-
|
-
|
-
|
|||||||||||||||||||||||||||||
Issuance of Common Stock to Brooklyn members
|
-
|
38,931,881
|
194,659
|
-
|
-
|
-
|
(194,659
|
)
|
-
|
-
|
-
|
|||||||||||||||||||||||||||||
Issuance of Common Stock to Financial Adviser upon consummation of Merger
|
-
|
1,067,879
|
5,339
|
-
|
-
|
-
|
5,761,207
|
(5,766,546
|
)
|
-
|
-
|
|||||||||||||||||||||||||||||
Transaction costs (to be paid in cash)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(1,048,915
|
)
|
-
|
(1,048,915
|
)
|
||||||||||||||||||||||||||||
Pro forma adjustment
|
$
|
(25,799,878
|
)
|
38,543,165
|
$
|
192,697
|
-
|
$
|
-
|
$
|
456,450
|
$
|
(86,941,786
|
)
|
$
|
129,071,852
|
$
|
(245,221
|
)
|
$
|
16,734,114
|
(1)
|
Not reflecting the effect of the 1-for-2 Reverse Stock Split.
|
E.
|
To eliminate the NTN business as a result of the Disposition.
|
F.
|
The pro forma combined basic and diluted net loss per share of Common Stock have been adjusted to reflect the pro forma net loss for the year ended December 31, 2020, and the number of
shares of Common Stock used in calculating the pro forma combined basic and diluted net loss per share of Common Stock has been adjusted to reflect the total number of shares of Common Stock of the giving effect to Reverse Stock Split
effective on the date of the Merger.
|
The following table sets forth the calculation of the pro forma weighted average number of shares of Common Stock outstanding – basic and diluted.
Year Ended
December 31, 2020
|
||||
Effect of applying the 1-for-2 Reverse Stock Split exchange ratio to historical NTN weighted average Common Stock outstanding, 2,928,160
|
1,464,080
|
|||
Shares of Common Stock issued to Brooklyn LLC members in the Merger
|
38,931,881
|
|||
Shares of Common Stock issued to the Financial Adviser upon consummation of Merger
|
1,067,879
|
|||
Pro forma weighted average number of shares of Common Stock outstanding
|
41,463,840
|
10
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DSV, 1104 - LAUNCH OF NEW SHARE BUYBACK PROGRAMME ACCORDING TO THE SAFE HARBOUR METHOD
- Heineken N.V. reports on 2024 first-quarter trading
- PetroTal Announces Corporate Updates
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!